Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Gaseous Precursor Filled Microspheres As Magnetic Resonance Imaging Contrast Agents - Patent 5922304

VIEWS: 21 PAGES: 47

1. Field of the InventionThis invention relates to the field of magnetic resonance imaging, more specifically to the use of stabilized gas filled microspheres as contrast media for magnetic resonance imaging (MRI).There are a variety of imaging techniques that have been used to diagnose disease in humans. One of the first imaging techniques employed was X-rays. In X-rays, the images produced of the patients' body reflect the different densities of bodystructures. To improve the diagnostic utility of this imaging technique, contrast agents are employed to increase the density of tissues of interest as compared to surrounding tissues to make the tissues of interest more visible on X-ray. Barium andiodinated contrast media, for example, are used extensively for X-ray gastrointestinal studies to visualize the esophagus, stomach, intestines and rectum. Likewise, these contrast agents are used for X-ray computed tomographic studies (that is, computerassisted tomography or CAT) to improve visualization of the gastrointestinal tract and to provide, for example, a contrast between the tract and the structures adjacent to it, such as the vessels or lymph nodes. Such contrast agents permit one toincrease the density inside the esophagus, stomach, intestines and rectum, and allow differentiation of the gastrointestinal system from surrounding structures.Magnetic resonance imaging (MRI) is a relatively new imaging technique which, unlike X-rays, does not utilize ionizing radiation. Like computer assisted tomography (CAT), MRI can make cross-sectional images of the body, however MRI has theadditional advantage of being able to make images in any scan plane (i.e., axial, coronal, sagittal or orthogonal). Unfortunately, the full utility of MRI as a diagnostic modality for the body is hampered by the need for new or better contrast agents. Without suitable agents, it is often difficult using MRI to differentiate the target tissue from adjacent tissues. If better contrast a

More Info
									


United States Patent: 5922304


































 
( 1 of 1 )



	United States Patent 
	5,922,304



 Unger
 

 
July 13, 1999




 Gaseous precursor filled microspheres as magnetic resonance imaging
     contrast agents



Abstract

Novel gas filled microspheres useful as magnetic resonance imaging (MRI)
     contrast agents are provided.


 
Inventors: 
 Unger; Evan C. (Tucson, AZ) 
 Assignee:


Imarx Pharmaceutical Corp.
 (Tucson, 
AR)





Appl. No.:
                    
 08/401,974
  
Filed:
                      
  March 9, 1995

 Related U.S. Patent Documents   
 

Application NumberFiling DatePatent NumberIssue Date
 212553Mar., 1994
 076250Jun., 1993
 716899Jun., 1991
 717084Jun., 19915228446
 716899
 569828Aug., 19915088499
 455707Dec., 1989
 717084
 569828Aug., 19905088499
 455707Dec., 1989
 076239Jun., 19935469854
 716899Jun., 1991
 717084Jun., 19915228446
 716899
 569828Aug., 19905088499
 455707Dec., 1989
 717084
 569828Aug., 19905088499
 455707Dec., 1989
 307305Sep., 19945773024
 212553Mar., 1994
 159687Nov., 19935585112
 160232Nov., 19935542935
 159687
 159674Nov., 1993
 159687Nov., 19935585112
 160232Nov., 19935542935
 159674Nov., 1993
 160232Nov., 19935542935
 159687Nov., 19935585112
 159674Nov., 1993
 

 



  
Current U.S. Class:
  424/9.3  ; 424/9.32; 424/9.321; 424/9.37; 424/9.52
  
Current International Class: 
  A61K 8/70&nbsp(20060101); A61K 9/127&nbsp(20060101); A61K 41/00&nbsp(20060101); A61K 49/18&nbsp(20060101); A61K 49/22&nbsp(20060101); A61K 47/48&nbsp(20060101); A61K 49/06&nbsp(20060101); A61K 8/14&nbsp(20060101); A61K 8/30&nbsp(20060101); G01R 33/28&nbsp(20060101); A61M 5/31&nbsp(20060101); A61B 005/055&nbsp(); A61K 049/04&nbsp()
  
Field of Search: 
  
  










 424/9.321,9.32,9.3,9.52,9.51,450,498,9.37 128/662.02,653.4 600/458
  

References Cited  [Referenced By]
U.S. Patent Documents
 
 
 
3015128
January 1962
Sommerville et al.

3293114
December 1966
Kenaga et al.

3479811
November 1969
Walters

3488714
January 1970
Walters et al.

3532500
October 1970
Priest et al.

3594326
July 1971
Himmel et al.

3615972
October 1971
Morehouse et al.

3650831
March 1972
Jungermann et al.

3732172
May 1973
Herbig et al.

3873564
March 1975
Schneider et al.

3945956
March 1976
Gerner

3960583
June 1976
Netting et al.

3968203
July 1976
Spitzer et al.

4027007
May 1977
Messina

4089801
May 1978
Schneider

4108806
August 1978
Cohrs et al.

4138383
February 1979
Rembaum et al.

4162282
July 1979
Fulwyler et al.

4179546
December 1979
Garner et al.

4192859
March 1980
Mackaness et al

4224179
September 1980
Schneider

4229360
October 1980
Schneider et al.

4265251
May 1981
Tickner

4276885
July 1981
Tickner et al.

4310505
January 1982
Baldeschwieler et al.

4310506
January 1982
Baldeschwieler et al.

4315514
February 1982
Drewes et al.

4331654
May 1982
Morris

4342826
August 1982
Cole

4344929
August 1982
Bonsen et al.

4420442
December 1983
Sands

4421562
December 1983
Sands et al.

4426330
January 1984
Sears

4428924
January 1984
Millington

4442843
April 1984
Rasor et al.

4466442
August 1984
Hilmann et al.

4533254
August 1985
Cook et al.

4534899
August 1985
Sears

4540629
September 1985
Sands et al.

4544545
October 1985
Ryan et al.

4549892
October 1985
Baker et al.

4569836
February 1986
Gordon

4572203
February 1986
Feinstein

4586512
May 1986
Do-huu et al.

4603044
July 1986
Geho et al.

4615879
October 1986
Runge et al.

4620546
November 1986
Aida et al.

4646756
March 1987
Watmough et al.

4657756
April 1987
Rasor et al.

4658828
April 1987
Dory

4675310
June 1987
Chapman et al.

4681119
July 1987
Rasor et al.

4684479
August 1987
D'Arrigo

4689986
September 1987
Carson et al.

4718433
January 1988
Feinstein

4728575
March 1988
Gamble et al.

4728578
March 1988
Higgins et al.

4731239
March 1988
Gordon

4737323
April 1988
Martin et al.

4774958
October 1988
Feinstein

4775522
October 1988
Clark, Jr.

4776991
October 1988
Farmer et al.

4781871
November 1988
West, III et al.

4789501
December 1988
Day et al.

4790891
December 1988
Halliday et al.

4822534
April 1989
Lencki et al.

4830858
May 1989
Payne et al.

4844882
July 1989
Widder et al.

4863717
September 1989
Keana

4865836
September 1989
Long, Jr.

4877561
October 1989
Iga et al.

4893624
January 1990
Lele

4895719
January 1990
Radhakrishnan

4898734
February 1990
Mathiowitz et al.

4900540
February 1990
Ryan et al.

4921706
May 1990
Roberts et al.

4927623
May 1990
Long, Jr.

4933121
June 1990
Law et al.

4938947
July 1990
Nicolau et al.

4957656
September 1990
Cerny et al.

4981692
January 1991
Popescu et al.

4985550
January 1991
Charpiot et al.

4987154
January 1991
Long, Jr.

4993415
February 1991
Long

4996041
February 1991
Arai et al.

5000960
March 1991
Wallach

5004611
April 1991
Leigh

5008050
April 1991
Cullis et al.

5013556
May 1991
Woodle et al.

5019370
May 1991
Jay et al.

5036003
July 1991
Olander et al.

5045304
September 1991
Schneider et al.

5049388
September 1991
Knight et al.

5078994
January 1992
Nair et al.

5088499
February 1992
Unger

5114703
May 1992
Wolf et al.

5123414
June 1992
Unger

5135000
August 1992
Akselrod et al.

5137928
August 1992
Erbel et al.

5141738
August 1992
Rasor et al.

5147631
September 1992
Glajch et al.

5149319
September 1992
Unger

5171755
December 1992
Kaufman

5186992
February 1993
Shell et al.

5190982
March 1993
Erbel et al.

5192549
March 1993
Barenolz et al.

5194266
March 1993
Abra et al.

5195520
March 1993
Schlief et al.

5196183
March 1993
Yudelson et al.

5198255
March 1993
Meybeck et al.

5205287
April 1993
Erbel et al.

5205290
April 1993
Unger

5209720
May 1993
Unger

5213804
May 1993
Martin et al.

5215680
June 1993
D'Arrigo

5219538
June 1993
Henderson et al.

5228446
July 1993
Unger et al.

5230882
July 1993
Unger

5247935
September 1993
Cline et al.

5271928
December 1993
Schneider et al.

5281408
January 1994
Unger

5305757
April 1994
Unger et al.

5310540
May 1994
Giddey et al.

5315997
May 1994
Widder et al.

5315998
May 1994
Tachibana et al.

5316771
May 1994
Barenholz et al.

5334381
August 1994
Unger

5344930
September 1994
Riess et al.

5350571
September 1994
Kaufmann et al.

5352435
October 1994
Unger

5354549
October 1994
Klaveness et al.

5358702
October 1994
Unger

5362478
November 1994
Desai et al.

5380519
January 1995
Schneider et al.

5393524
February 1995
Quay

5409688
April 1995
Quay

5410516
April 1995
Uhlendorf et al.

5413774
May 1995
Schneider et al.

5425366
June 1995
Reinhardt et al.

5433204
July 1995
Olson

5445813
August 1995
Schneider et al.

5456900
October 1995
Unger

5469854
November 1995
Unger et al.

5470582
November 1995
Supersaxo et al.

5487390
January 1996
Cohen et al.

5496535
March 1996
Kirkland

5498421
March 1996
Grinstaff et al.

5501863
March 1996
Rossling et al.

5502094
March 1996
Moore et al.

5505932
April 1996
Grinstaff et al.

5527521
June 1996
Unger

5529766
June 1996
Klaveness et al.

5531980
July 1996
Schneider et al.

5536489
July 1996
Lohrmann et al.

5536490
July 1996
Klaveness et al.

5540909
July 1996
Schutt

5542935
August 1996
Unger et al.

5547656
August 1996
Unger

5552133
September 1996
Lambert et al.

5556610
September 1996
Yan et al.

5558092
September 1996
Unger et al.

5558094
September 1996
Quay

5558853
September 1996
Quay

5558854
September 1996
Quay

5558855
September 1996
Quay

5558856
September 1996
Klaveness et al.

5560364
October 1996
Porter

5562893
October 1996
Lohrmann

5567413
October 1996
Klaveness et al.

5567414
October 1996
Schneider et al.

5567765
October 1996
Moore et al.

5569449
October 1996
Klaveness et al.

5573751
November 1996
Quay

5578292
November 1996
Schneider et al.

5585112
December 1996
Unger et al.

5595723
January 1997
Quay

5605673
February 1997
Schutt et al.

5606973
March 1997
Lambert et al.

5614169
March 1997
Klaveness et al.

5620689
April 1997
Allen et al.

5626833
May 1997
Schutt et al.

5639443
June 1997
Schutt et al.

5643553
July 1997
Schneider et al.

5672585
September 1997
Pierschbacher et al.

5676928
October 1997
Klaveness et al.

5686060
November 1997
Schneider et al.

5707606
January 1998
Quay

5707607
January 1998
Quay

B14229360
November 1991
Schneider et al.



 Foreign Patent Documents
 
 
 
641363
Mar., 1990
AU

B-30351/89
Mar., 1993
AU

0 007 752 B1
Oct., 1982
EP

0 107 559
May., 1984
EP

0 243 947
Apr., 1987
EP

0 231 091
Aug., 1987
EP

0 272 091
Jun., 1988
EP

0 320 433 A2
Dec., 1988
EP

0 324 938
Jul., 1989
EP

0 338 971
Oct., 1989
EP

357 163 A1
Mar., 1990
EP

0 361 894
Apr., 1990
EP

0 216 730
Jan., 1991
EP

0 467 031 A2
May., 1991
EP

441 468 A2
Aug., 1991
EP

0 357 164 B1
Oct., 1991
EP

0 458 745 A1
Nov., 1991
EP

0 314 764 B1
Sep., 1992
EP

0 554 213 A1
Aug., 1993
EP

0 586 875
Mar., 1994
EP

72 255 A2
Aug., 1996
EP

62 286534
Dec., 1987
JP

63-60943
Mar., 1988
JP

1044680
Oct., 1966
GB

2193095
Feb., 1988
GB

WO 80/02365
Nov., 1980
WO

WO 82/01642
May., 1982
WO

85/01161
Mar., 1985
WO

WO 86/00238
Jan., 1986
WO

WO 86/01103
Feb., 1986
WO

WO 89/05040
Jun., 1989
WO

WO 90/01952
Mar., 1990
WO

WO 90/04384
May., 1990
WO

WO 90/04943
May., 1990
WO

WO 91/00086
Jan., 1991
WO

WO 91/12823
Sep., 1991
WO

WO 91/15244
Oct., 1991
WO

WO 92/10166
Jun., 1992
WO

WO 92/11873
Jul., 1992
WO

WO 92/17514
Oct., 1992
WO

WO 92/17212
Oct., 1992
WO

WO92/17213
Oct., 1992
WO

WO92/17436
Oct., 1992
WO

WO92/21382
Dec., 1992
WO

WO 93/00993
Jan., 1993
WO

WO 93/05819
Jan., 1993
WO

WO 93/06869
Apr., 1993
WO

WO 93/13809
Jul., 1993
WO

WO 93/13808
Jul., 1993
WO

9317718
Sep., 1993
WO

WO93/18070
Sep., 1993
WO

WO 93/20802
Oct., 1993
WO

WO 94/06477
Mar., 1994
WO

WO 94/07539
Apr., 1994
WO

WO 94/09829
May., 1994
WO

WO94/16739
Aug., 1994
WO

WO 94/21302
Sep., 1994
WO

WO 94/28780
Dec., 1994
WO

WO 95/07072
Mar., 1995
WO

WO 95/06518
Mar., 1995
WO

WO 95/23615
Sep., 1995
WO

WO 96/04018
Feb., 1996
WO

WO 96/09793
Apr., 1996
WO

WO 96/36286
Nov., 1996
WO



   
 Other References 

Sigel, H., ed., Metal Ions in Biological Systems: Antibiotics and Their Complexes, vol. 19 (Marcel Dekker, N.Y.),(1985).
.
Nayar et al., "Generation of Large Unilamellar Vesicles From Long-chain Saturated Phosphatidylcholines by Extrusion Technique", Biochimica et Biophysica Acta, vol. 986, pp. 200-206 (1989).
.
Hope et al., "Generation of Multilamellar and Unilamellar Phospholipid Vesicles", Chemistry and Physics of Lipids, vol. 40, pp. 89-107 (1986).
.
Mattrey et al., "Perfluorochemicals as US Contrast Agents for Tumor-Imaging and Hepatosplenography: Preliminary Clinical Results", Radiology, vol. 163, pp. 339-343 (1987).
.
Mattrey et al., "Perfluoroctylbromide: A Liver/Spleen-Specific and Tumor Imaging Ultrasound Contrast Material", Radiology, vol. 145, pp. 759-762 (1982).
.
Keller et al., "Successful Left Ventricular Opacification Following Peripheral Venous Injection of Sonicated Contrast Agent: An Experimental Evaluation", LV Contrast Echocardiography, vol. 114, No. 3, pp. 570-575 (1987).
.
Feinstein et al., "Two-Dimensional Contrast Echocardiography, I: In Vitro Development and Quantitative Analysis of Echo Contrast Agents", JACC, vol. 3, No. 1, pp. 14-20 (1984).
.
Ten Cate et al., "Two-Dimensional Contrast Echocardiography, II: Transpulmonary Studies", JACC, vol. 3, No. 1, pp. 21-27 (1984).
.
Unger et al., "Hepatic Metastases: Liposomal Gd-DTPA-enhanced MR Imaging", Radiology, vol. 171, pp. 81-85 (1989).
.
Deamer et al., "Permeability of Lipid Bilayers to Water and Ionic Solutes", Chemistry and Physics of Lipids, vol. 40, pp. 167-188 (1986).
.
Gutknecht et al., "Diffusion of Carbon Dioxide Through Lipid Bilayer Membranes: Effect of Carbonic Anhydrase, Bicarbonate, and Unstirred Layers", Chemical Abstracts, 87:34772q (1977).
.
Scarpa et al., "Cation Permeability of Liposomes as a Function of the Chemical Composition of the Lipid Bilayers", Biochimica et Biophysica Acta, vol. 241, pp. 789-797 (1971).
.
MacNaughton et al., "Effects of Gaseous Anesthetics and Inert Gases on the Phase Transition in Smectic Mesophases of Dipalmitoyl Phosphatidylcholine", Biochimica et Biophysica Acta, vol. 597, pp. 193-198 (1980).
.
Tilcock et al., "Liposomal Gd-DTPA: Preparation and Characterization of Relaxivity", Radiology, vol. 171, pp. 77-80 (1989).
.
Mann et al., "Formation of Iron Oxides in Unilamellar Vesicles", Journal of Colloid and Interface Science, vol. 122, No.2, pp. 326-335 (1988).
.
Anderson et al., "Manganese (III) Complexes in Oxidative Decarboxylation of Acids", J. Am. Chem. Soc., vol. 92, No.8, pp. 2450-2460 (1970).
.
Muhlradt et al., "Vitamin B6 Analogs: An Improved Synthesis of 5-Deoxypyridoxal", New Compounds, vol. 10, pp. 129-130 (1967).
.
Chapman D., "Physiochemical Properties of Phospholipids and Lipid Water Systems", Liposome Technology, Gregoriadis, G., ed., vol. 1, pp. 1-19 (CRC Press, Boca Raton, FL, 1984).
.
Violante et al., "Particulate Suspensions as Ultrasonic Contrast Agents for Liver And Spleen", Inv. Rad., vol. 23, pp. S294-S297, Sep. 1988.
.
Fritzsch et al., "Preclinical and Clinical Results with an Ultrasonic Contrast Agent", Inv. Rad., vol. 23, pp. S302-S305, Sep. 1988.
.
Brochure, Experience, Sonicator.TM., Heat Systems-Ultrasonics, Inc. (1987).
.
M. Ostro, "Liposomes", Marcel Dekker, New York, pp. 102-103 (1983).
.
Fukuda et al., "Polymer-Encased Vesicles Derived from Diotadecyldimethylammonium Methacrylate", J. Am. Chem. Soc., vol. 108, pp. 2321-2327 (1986).
.
Regen, "Polymerized Vesicles", J. Am. Chem. Soc., vol. 102, pp. 6638-6640 (1989).
.
Rose, A. and Rose, E., "The Condensed Chemical Dictionary", Reinhold Publishing, New York, pp. 728 and 743 (1966).
.
A.G. Belykh, Farmakol Toksikol. (MOSC), vol. 44(3), pp. 322-326 (1981) (abstract).
.
J. Vion-Dury et al., J. Pharmacol. Exper. Ther., vol. 250(3), pp. 1113-1118 (1989) (abstract).
.
M.R. Zalutsky et al., Invest. Radiol., vol. 22(2), pp. 141-147 (1987) (abstract).
.
Crowe et al., Archives of Biochemistry and Biophysics, vol. 242, pp. 240-247 (1985).
.
Crowe et al., Archives of Biochemistry and Biophysics, vol. 220, pp. 477-484 (1983).
.
Dorland's Illustrated Medical Dictionary, p. 946, 27th ed. (W.B. Saunders Company, Philadelphia 1988).
.
Liposome Technology, Gregoriadis, G., ed., vol. I, pp. 1-18, 29-35, 51-65 and 79-107 (CRC Press Inc., Boca Raton, FL, (1984).
.
Madden et al., Chemistry and Physics of Lipids, vol. 53, pp. 37-46 (1990).
.
Sinkula et al., J. Pharm. Sci., vol. 64, pp. 181-210 (1975).
.
Shiina et al., "Hyperthermiaby Low-frequency Synthesized Ultrasound", IEEE Engineering, pp. 879-880, vol. 2 (abstract), (1987).
.
McAvoy et al., IEEE Engineering, Ultrasonics Symposium Proceedings, vol. 2, pp. 677-1248 (abstract), (1989).
.
Chapman et al., "Biomembrane Phase Transitions", J. Biol. Chem., 1974, 249:2512-2521.
.
Hug et al., "Liposomes for the Transformation of Eukaryotic Cells", Biochimica et Biophysica Acta, 1991, 1097:1-17.
.
Marsh, CRC Handbook of Lipid Bilayers (CRC Press, Boca Raton, FL 1990) pp. 139-141.
.
Szoka et al., "Procedure for Preparation of Liposomes With Large Internal Aqueous Space . . . ", Proc. Natl. Acad. Sci. 1978, 75:4194-4198.
.
Acoustic Imaging; AI5200; Convex Curved Linear Array Ultrasound Transducers Operator's Manual, Nov. 20, 1989, 4700-0003-1C, p. 4.
.
Bangham et al., "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids", J. Mol. Biol., 1965, 13:238-252.
.
Carson et al., Ultrasound in Med. & Biol. 3, 1978, 341-350.
.
Chiellini et al., Polymers in Medicine II: Biomedical and Pharmaceutical Applications, (Plenum Press, New York and London) pp. 387-396, (1983).
.
deGier et al., "Relations Between Liposomes and Biomembranes", Annals of The New York Academy of Sciences, 1978, 308:85-99.
.
Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", Proc. Natl. Acad. Sci., 1987, 84:7413-7417.
.
Gabizon et al., "Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors", Proc. Natl. Acad. Sci., 1988, 85:6949-6953.
.
Garelli, et al., Biochimica et Biophysica Acta, vol. 1127:41-48 (1992).
.
Kawai et al., "New Procedure for DNA Transfection with Polycation and Dimethyl Sulfoxide", Molecular and Cellular Biology, 1984, 4:1172-1174.
.
Kuo et al., "Metallocene Antitumor Agents. Solution and Solid-State Molybdenocene Coordination . . . ", J. Am. Chem. Soc., 1991, 113:9027-9045.
.
Mammalian Cell Biotechnology: A Practical Approach, M. Butler, 1991 (Oxford University Press, New York), pp. 57-70.
.
Mathiowitz et al., "Photochemical Rupture of Microcapsules: A Model System", Journal of Applied Polymer Science, 1981, 26:809-822.
.
May et al., "Cationic Liposomes Enable Bovine Herpesvirus Type 2 DNA to Infect Cells", Acta virol., 1991, 35:107.
.
Poznansky et al., "Biologica Approaches to the Controlled Delivery of Drugs: A Critical Review", Pharmacol, Rev., 1984, 36:277-336.
.
Sato et al., "Recent Aspects in the Use of Liposomes in Biotechnology and Medicine", Prog. Lipid Res. 1992, 4:345-372.
.
Simons et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo", Nature, 1992, 359:67-70.
.
Thompson, Larry, "At Age 2, Gene Therapy Enters a Growth Phase", Science 1992, 258:744-746.
.
Trubetskoy et al. "Cationic liposomes enhance targeted delivery and expression of exogenous DNA . . . ", Biochimica et Biophysica Acta 1992, 131:311-313.
.
Umemura et al., "Studies on Sonodynamic Cancer Therapy", IEEE, 1992, O-7803-0785, pp. 354-355.
.
Williams, "Human Gene Therapy: Searching for Better Vectors", ASM News [American Society for Microbology] 1992, 58:67-69.
.
Woodle et al., "Versatility in lipid compositions showing prolonged circulation . . . ", Biochimica et Biophysica Acta 1992, 1105:193-200.
.
Zhou et al., "Targeted delivery of DNA by liposomes and polymers", J. of Controlled Release 1992, 19:269-274.
.
Mathiowitz et al., "Polyanhydride Microspheres as Drug Carriers", Journal of Applied Polymer Science, vol. 35, pp. 755-774 (1988).
.
Sankaram et al., "Cholesterol-Induced Fluid-Phase Immiscibility in Membranes", Proc. Natl. Acad. Sci., vol. 88, pp. 8686-8690 (1991).
.
Scientific Apparatus Catalog 92/93 (VWR Scientific, 1991), "Syringes", pp. 1511-1513; "Filtration, Syringe Filters", pp. 766-768; "Filtration, Membranes", pp. 750-753; "Filtration, Filter Holders", p. 744, (1991).
.
Gramiak et al., Radiology, "Detection of Intracardiac Blood Flow by Pulsed Echo-Ranging", pp. 415-418 (1971).
.
Feigenbaum et al., Circulation, "Identification of Ultrasound Echoes from the Left Ventricle by Use of Intracardiac Injections of Indocyanine Green", vol. XL1, pp. 615-621 (1970).
.
Santaella, et al., FEBS 13463, "Extended In Vivo Blood Circulation Time of Fluorinated Liposomes", vol. 336, No. 3, pp. 481-484 (1993).
.
Kost, et al, Polymers in Medicine II, Ultrasonic Modulated Drug Delivery Systems, pp. 387-396, (1988).
.
Brown and Langer, Annual Review Medicine, 1988, 39:221 29, Annual Review, Inc., "Transdermal Delivery of Drugs", pp. 221-229.
.
Moseley, et al., Microbubbles: A Novel MR Susceptibility Contrast Agent, abstract, 1991 Napa, California Meeting of the Society for Magnetic Resonance in Medicine.
.
Ter-Pogossian, Physical Principles and Instrumentation, "Computed Body Tomography", Chapter 1, pp. 1-7, (1985).
.
Aronberg, Techniques, "Computed Body Tomography", Chapter 2, pp. 9-36, (1985).
.
Miller Ultrasonics (Sep. 1981), "Ultrasonic detection of resonant cavitation bubbles in a flow tube by their second-harmonic emissions," pp. 217-224.
.
Dittrich, "Cardiac Muscle Ischemia and Infarction", The Second Annual Int. Symposium on Contrast Agents and Diagnostic Ultrasound, Atlantic City, NJ (May 7, 1996) (Abstract).
.
Pantely, "Intravenous Contrast Echocardiography-Tissue Imaging & Quantification of Coronary Blood Flow", The Second Annual Int. Symposium on Contrast Agents in Diagnostic Ultrasound, Atlantic City, NJ (May 7, 1996) (Abstract).
.
Lincoff et al., "Intravitreal Expansion of Perfluorocarbon Bubbles", Arch. Ophthalmol., 1980, 98, 1646.
.
Lincoff et al., "Intravitreal Longevity of Three Perfluorocarbon Gases", Arch. Ophthalmol., 1980, 98, 1610-1611.
.
Lincoff et al., "The Perfluorocarbon Gases in the Treatment of Retinal Detachment", Ophthalmology, 1983, 90(5), 546-551.
.
Gardner et al., "A Survey of Intraocular Gas Use in North America", Arch. Ophthalmol., 1988, 106, 1188-1189.
.
Unger et al., "Liposomal MR Contrast Agents", J. Liposome Research, 1994, 4(2), 811-834.
.
Schutt et al., "Osmotically Stabilized Microbubble Sonographic Contrast Agents", Acad. Radiol., 1996, 3 (Suppl. 2), S188-S190.
.
Frezard et al., "Permeability and stability in buffer and in human serum of fluorinated phospholipid-based liposomes", Biochimica et Biophysica Acta, 1994, 1192, 61-70.
.
Frezard et al., "Fluorinated Phospholipid-Based Vesicles as Potential Drug Carriers: Encapsulation/Sustaining of Drugs and Stability in Human Serum", Art, Cells, Blood Subs., and Immob. Biotech., 1994, 22(4), 1403-1408.
.
Chang et al., Semipermeable Aqueous Microcapsules Canadian J. Of Phys. And Pharm, 1966, 44, 115-128.
.
Chang, "Semipermeable Microcapsules", Science, 1964, 146, 524-525.
.
Deasy, Microencapsulation and Related Drug Processes, 1983, 20 (Ch. 9 & 10), 195-240 (Marcell Dekker, Inc., NY).
.
Yeung et al., "Preparation of Microencapsulated Liposomes", J. Microencapsulation, 1988, 5, 331-337.
.
Mattrey et al., Gas Emulsions as Ultrasound Contrast Agents; Preliminary Results in Rabbits and Dogs, Investigative Radiology, 1994, vol. 29, (Jun. Supp. 2), S139-S141.
.
Meltzer et al., Transmission of Ultrasonic Contrast Through the Lungs, Ultrasound in Med. & Biol., 1981, 7(4), 377-384.
.
PR Newswire, Apr. 1, 1986.
.
Swanson et al., "Enhancement Agents for Ultrasound: Fundamentals", Pharmaceuticals In Medical Imaging, 1990, Ch. 22, 682-687.
.
Ophir et al., "Contrast Agents in Diagnostic Ultrasound", Ultrasound in Med. & Biol., vol. 15, No. 4, pp. 319-333 (1989).
.
Jacobs, P., "Intraocular gas measurement using A-scan ultrasound", Current Eye Research, 1986, 5, 575-578.
.
Villanueva et al., "Characterization of Spatial Patters of Flow Within the Reperfused Myocardium by Myocardial Contrast Echocardiography", Circulation, vol. 88, No. 6, pp. 2596-2606 (Dec. 1993).
.
Desir et al., "Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis", Am. Heart J., Jan., 1994, 127(1), 56-63.
.
Sekins et al., "Lung Cancer Hyperthermia via Ultrasound and PFC Liquids", Published in Proceedings of 5th International Symposium on Hyperthermic Oncology, Kyoto, Japan, Aug. 29-Sep. 3, 1998, 3 pages.
.
Pietersen, "A New Warning System for Fires of Electrical Origin", CERN European Organization for Nuclear Research, Health and Safety Division, Mar., 1977, 1-5.
.
Feinstein, Steven B., "Myocardial Perfusion Imaging: Contrast Echocardiography Today and Tomorrow," Journal of the American College of Cardiology, 8(1):251-253 (1986).
.
Keller et al., "The Behavior of Sonicated Albumin Microbubbles Within the Microcirulation: A Basis for Their Use During Myocardial Contrast Echocardiography", Circulation Res., 65(2):458-465 (1989).
.
Lincoff et al., "Perfluoro-n-butane: A Gas for Maximum Duration Retinal Tamponade," Arch Ophthalmology, 101:460-462 (1983).
.
Remington's Pharmaceutical Sciences, John Hoover, managing ed., Mack Publishing Company, Easton, PA, pp. 295-298; 736; 1242-1244 (1975).
.
Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington, D.C. and The Pharmaceutical Society of Great Britain, London, England, pp. 181-183 (1986).
.
Miller et al., "Physiochemical Approaches to the Mode of Action of General Anesthetics," J. Amer. Soc. Anesthesiologists, 36(4):339-351 (1972).
.
"Properties and Applications of the `Freon` Fluorocarbons" in DuPont Freon Technical Bulletin B-2 (E.I. DuPont de Nemours and Company, Wilmington, DE), pp. 1-11 (1964).
.
"`Freon` Fluorocarbons: Properties and Applications" in DuPont Technical Bulletin G-1 (E.I. DuPont de Nemours and Company, Wilmington, DE), pp. 1-10 (1987).
.
"Encyclopedia of Polymer Science and Engineering," John Wiley & Sons, New York, 1:164-169 (1985).
.
"Concise Encyclopedia of Polymer Science and Engineering," J. Kroschwitz, ed., John Wiley & Sons, New York, pp. 12-13 (1990).
.
Wheatley et al., "Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles," Biomaterials, 11:713-717 (1990)..  
  Primary Examiner:  Dees; Jose'G.


  Assistant Examiner:  Hartley; Michael G.


  Attorney, Agent or Firm: Woodcock Washburn Kurtz Mackiewicz & Norris LLP



Parent Case Text



REFERENCE TO COPENDING APPLICATIONS


This application is a continuation-in-part of U.S. Ser. No. 08/212,553
     filed Mar. 11, 1994, now abandoned.


This application is also a continuation-in-part of U.S. Ser. No. 08/076,250
     filed Jun. 11, 1993, now U.S. Pat. No. 5,580,575, which is a
     continuation-in-part of U.S. Ser. No. 07/716,899 filed Jun. 18, 1991, now
     abandoned, and U.S. Ser. No. 07/717,084 filed Jun. 18, 1991, now U.S. Pat.
     No. 5,228,446, both of which are continuations-in-part of U.S. Ser. No.
     07/569,828 filed Aug. 20, 1990, now U.S. Pat. No. 5,088,499, which in turn
     is a continuation-in-part of U.S. Ser. No. 07/455,707 filed Dec. 22, 1989,
     now abandoned. Ser. No. 08/076,250 discloses therapeutic drug delivery
     systems comprising gas filled microspheres containing a therapeutic agent,
     with particular emphasis on the use of ultrasound techniques to monitor
     and determine the presence of said microspheres in a patient's body, and
     then to rupture said microspheres in order to release said therapeutic
     agent in the region of the patient's body where said microspheres are
     found.


This application is also a continuation-in-part of U.S. Ser. No. 08/076,239
     filed Jun. 11, 1993, now U.S. Pat. No. 5,469,854, which is a
     continuation-in-part of U.S. Ser. No. 07/716,899 filed Jun. 18, 1991, now
     abandoned, and U.S. Ser. No. 07/717,084 filed Jun. 18, 1991, now U.S. Pat.
     No. 5,229,446, both of which are continuations-in-part of U.S. Ser. No.
     07/569,828 filed Aug. 20, 1990, now U.S. Pat. No. 5,088,499, which in turn
     is a continuation-in-part of U.S. Ser. No. 07/455,707 filed Dec. 22, 1989,
     now abandoned. Ser. No. 08/076,239 discloses methods and apparatus for
     preparing gas filled microspheres suitable for use as contrast agents for
     ultrasonic imaging or as drug delivery agents.


This application is also a continuation-in-part of U.S. Ser. No. 08/307,305
     filed Sep. 16, 1994, U.S. Pat. No. 5,773,024, which is a
     continuation-in-part of U.S. Ser. No. 08/212,553, filed Mar. 11, 1994, now
     abandoned, and U.S. Ser. No. 08/159,687 filed Nov. 30, 1993, now U.S. Pat.
     No. 5,585,112, which is a continuation-in-part of U.S. Ser. No.
     08/160,232, filed Nov. 30, 1993, now U.S. Pat. No. 5,542,935 and U.S. Ser.
     No. 08/159,674 filed Nov. 30, 1993, now abandoned.


This application is also a continuation-in-part of U.S. Ser. No. 08/159,687
     filed Nov. 30, 1993, now U.S. Pat. No. 5,585,112, which is a
     continuation-in-part of U.S. Ser. No. 08/160,232 filed Nov. 30, 1993, now
     U.S. Pat. No. 5,542,935, and U.S. Ser. No. 08/159,674 filed Nov. 30, 1993,
     now abandoned.


This application is also a continuation-in-part of U.S. Ser. No.
     08/160,232, filed Nov. 30, 1993, now U.S. Pat. No. 5,542,935, which is a
     continuation-in-part of U.S. Ser. No. 08/159,687 filed Nov. 30, 1993, now
     U.S. Pat. No. 5,585,112, and U.S. Ser. No. 08/159,674 filed Nov. 30, 1993,
     now abandoned.


Application Ser. Nos. 08/307,305, 08/159,687 and 08/160,232 disclose novel
     therapeutic delivery systems and methods of preparing gas and gaseous
     precursor filled microspheres and multiphase lipid and gas compositions
     useful in diagnostic and therapeutic applications.


Benefit of the filing dates of applications Ser. Nos. 08/212,553,
     08/307,305, 08/159,687, 08/160,232, 08/076,239 and 08/076,250 and their
     parentage is hereby claimed, and they are incorporated herein by reference
     in their entirety.


Reference is also made to application Ser. No. 07/507,125 filed Apr. 10,
     1990, which discloses the use of biocompatible polymers, either alone or
     in admixture with one or moire contrast agents such as paramagnetic,
     superparamagnetic or proton density contrast agents. The polymers or
     polymer/contrast agent admixtures may optionally be admired with one or
     more biocompatible gases to increase the relaxivity of the resultant
     preparation.

Claims  

What is claimed is:

1.  A method of providing an image of an internal region of a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said
microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas
in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of said region.


2.  A method for diagnosing the presence of a diseased tissue or region in a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and
consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using
magnetic resonance imaging to obtain visible images of any diseased tissue or region in the patient.


3.  A method according to claim 1 or 2 wherein the region is the vasculature.


4.  A method according to claim 1 or 2 wherein the region is the cardiovascular region.


5.  A method according to claim 1 or 2 wherein the region is the gastrointestinal region.


6.  A method according to claim 1 or 2 wherein the scanning is of the vasculature of the patient.


7.  A method according to claim 1 or 2 wherein the scanning is of the cardiovascular region of the patient.


8.  A method according to claim 1 or 2 wherein the scanning is of the gastrointestinal region of the patient.


9.  A method according to claim 1 or 2 wherein the scanning is of a region of the patient selected from the following: intranasal tract;  auditory canal;  intraocular region;  intraperitoneal region;  kidneys;  urethra;  and genitourinary tract.


10.  A method of claim 1 wherein said lipid is a phospholipid.


11.  A method of claim 2 wherein said lipid is a phospholipid.


12.  A method of claim 1 wherein said microsphere comprises a monolayer.


13.  A method of claim 12 wherein said monolayer comprises a phospholipid.


14.  A method of claim 2 wherein said microsphere comprises a monolayer.


15.  A method of claim 14 wherein said monolayer comprises a phospholipid.


16.  A method of claim 1 wherein said gaseous precursor is a perfluorocarbon.


17.  A method of claim 11 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane,
perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.


18.  A method of claim 17 wherein said gaseous precursor is perfluorohexane.


19.  A method of claim 17 wherein said gaseous precursor is perfluoropropane.


20.  A method of claim 17 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.


21.  A method of claim 20 wherein said gaseous precursor is perfluoropentane.


22.  A method of claim 1 wherein said microsphere is rehydrated from a lyophilized microsphere.


23.  A method of claim 1 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.


24.  A method of claim 1 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and
wherein said second lipid bears a hydrophilic polymer.


25.  A method of claim 24 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.


26.  A method of claim 25 wherein said negatively charged lipid is phosphatidic acid.


27.  A method of claim 24 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.


28.  A method of claim 24 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic-acid, and about 10 mole percent of
dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.


29.  A method of claim 24 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of
dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.


30.  A method of claim 2 wherein said gaseous precursor is a perfluorocarbon.


31.  A method of claim 2 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane,
perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.


32.  A method of claim 31 wherein said gaseous precursor is perfluorohexane.


33.  A method of claim 31 wherein said gaseous precursor is perfluoropropane.


34.  A method of claim 31 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.


35.  A method of claim 31 wherein said gaseous precursor is perfluoropentane.


36.  A method of claim 2 wherein said microsphere is rehydrated from a lyophilized microsphere.


37.  A method of claim 2 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.


38.  A method of claim 2 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and
wherein said second lipid bears a hydrophilic polymer.


39.  A method of claim 38 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.


40.  A method of claim 39 wherein said negatively charged lipid is phosphatidic acid.


41.  A method of claim 38 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.


42.  A method of claim 38 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic acid, and about 10 mole percent of
dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.


43.  A method of claim 38 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of
dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.  Description  

BACKGROUND OF THE INVENTION


1.  Field of the Invention


This invention relates to the field of magnetic resonance imaging, more specifically to the use of stabilized gas filled microspheres as contrast media for magnetic resonance imaging (MRI).


There are a variety of imaging techniques that have been used to diagnose disease in humans.  One of the first imaging techniques employed was X-rays.  In X-rays, the images produced of the patients' body reflect the different densities of body
structures.  To improve the diagnostic utility of this imaging technique, contrast agents are employed to increase the density of tissues of interest as compared to surrounding tissues to make the tissues of interest more visible on X-ray.  Barium and
iodinated contrast media, for example, are used extensively for X-ray gastrointestinal studies to visualize the esophagus, stomach, intestines and rectum.  Likewise, these contrast agents are used for X-ray computed tomographic studies (that is, computer
assisted tomography or CAT) to improve visualization of the gastrointestinal tract and to provide, for example, a contrast between the tract and the structures adjacent to it, such as the vessels or lymph nodes.  Such contrast agents permit one to
increase the density inside the esophagus, stomach, intestines and rectum, and allow differentiation of the gastrointestinal system from surrounding structures.


Magnetic resonance imaging (MRI) is a relatively new imaging technique which, unlike X-rays, does not utilize ionizing radiation.  Like computer assisted tomography (CAT), MRI can make cross-sectional images of the body, however MRI has the
additional advantage of being able to make images in any scan plane (i.e., axial, coronal, sagittal or orthogonal).  Unfortunately, the full utility of MRI as a diagnostic modality for the body is hampered by the need for new or better contrast agents. 
Without suitable agents, it is often difficult using MRI to differentiate the target tissue from adjacent tissues.  If better contrast agents were available, the overall usefulness of MRI as an imaging tool would improve, and the diagnostic accuracy of
this modality would be greatly enhanced.


MRI employs a magnetic field, radio frequency energy and magnetic field gradients to make images of the body.  The contrast or signal intensity differences between tissues mainly reflect the T1 (longitudinal) and T2 (transverse) relaxation values
and the proton density (effectively, the free water content) of the tissues.  In changing the signal intensity in a region of a patient by the use of a contrast medium, several possible approaches are available.  For example, a contrast medium could be
designed to change either the T1, the T2 or the proton density.


2.  Brief Description of the Prior Art


In the past, attention has mainly been focused on paramagnetic contrast media for MRI.  Paramagnetic contrast agents contain unpaired electrons which act as small local magnets within the main magnetic field to increase the rate of longitudinal
(T1) and transverse (T2) relaxation.  Most paramagnetic contrast agents are metal ions which in most cases are toxic.  In order to decrease toxicity, these metal ions are generally chelated using ligands.  The resultant paramagnetic metal ion complexes
have decreased toxicity.  Metal oxides, most notably iron oxides, have also been tested as MRI contrast agents.  While small particles of iron oxide, e.g., under 20 nm diameter, may have paramagnetic relaxation properties, their predominant effect is
through bulk susceptibility.  Therefore magnetic particles have their predominant effect on T2 relaxation.  Nitroxides are another class of MRI contrast agent which are also paramagnetic.  These have relatively low relaxivity and are generally less
effective than paramagnetic ions as MRI contrast agents.  All of these contrast agents can suffer from some toxic effects in certain use contexts and none of them are ideal for use as perfusion contrast agents by themselves.


The existing MRI contrast agents suffer from a number of limitations.  For example, positive contrast agents are known to exhibit increased image noise arising from intrinsic peristaltic motions and motions from respiration or cardiovascular
action.  Positive contrast agents such as Gd-DTPA are subject to the further complication that the signal intensity depends upon the concentration of the agent as well as the pulse sequence used.  Absorption of contrast agent from the gastrointestinal
tract, for example, complicates interpretation of the images, particularly in the distal portion of the small intestine, unless sufficiently high concentrations of the paramagnetic species are used (Kornmesser et al., Magn.  Reson.  Imaging, 6:124
(1988)).  Negative contrast agents, by comparison, are less sensitive to variation in pulse sequence and provide more consistent contrast.  However at high concentrations, particulates such as ferrites can cause magnetic susceptibility artifacts which
are particularly evident, for example, in the colon where the absorption of intestinal fluid occurs and the superparamagnetic material may be concentrated.  Negative contrast agents typically exhibit superior contrast to fat, however on T1-weighted
images, positive contrast agents exhibit superior contrast versus normal tissue.  Since most pathological tissues exhibit longer T1 and T2 than normal tissue, they will appear dark on T1-weighted and bright on T2-weighted images This would indicate that
an ideal contrast agent should appear bright on T1-weighted images and dark on T2-weighted images.  Many of the currently available MRI contrast media fail to meet these dual criteria.


Toxicity is another problem with the existing contrast agents.  With any drug there is some toxicity, the toxicity generally being dose related.  With the ferrites there are often symptoms of nausea after oral administration, as well as
flatulence and a transient rise in serum iron.  The paramagnetic contrast agent Gd-DTPA is an organometallic complex of gadolinium coupled with the complexing agent diethylene triamine pentaacetic acid.  Without coupling, the free gadolinium ion is
highly toxic.  Furthermore, the peculiarities of the gastrointestinal tract, for example, wherein the stomach secretes acids and the intestines release alkalines, raise the possibility of decoupling and separation of the free gadolinium or other
paramagnetic agent from the complex as a result of these changes in pH during gastrointestinal use.  Certainly, minimizing the dose of paramagnetic agents is important for minimizing any potential toxic effects.


New and/or better contrast agents useful in magnetic resonance imaging are needed.  The present invention is directed, inter alia, to this important end.


In the work on MRI contrast agents described above for application Ser.  No. 07/507,125, filed Apr.  10, 1990, it has been disclosed how gas can be used in combination with polymer compositions and paramagnetic or superparamagnetic agents as MRI
contrast agents.  Therein it has been shown how the gas stabilized by said polymers would function as an effective susceptibility contrast agent to decrease signal intensity on T2 weighted images; and that such systems are particularly effective for use
as gastrointestinal MRI contrast media.


Widder et al. published application EP-A-0 324 938 discloses stabilized microbubble-type ultrasonic imaging agents produced from heat-denaturable biocompatible protein, e.g., albumin, hemoglobin, and collagen.


There is also mentioned a presentation believed to have been made by Moseley et al., at a 1991 Napa, Calif.  meeting of the Society for Magnetic Resonance in Medicine, which is summarized in an abstract entitled "Microbubbles: A Novel MR
Susceptibility Contrast Agent".  The microbubbles which are utilized comprise air coated with a shell of human albumin.  The stabilized gas filled microspheres of the present invention are not suggested.


For intravascular use, however, the inventors have found that for optimal results, it is advantageous that any gas be stabilized with flexible compounds.  Proteins such as albumin may be used to stabilize the bubbles but the resulting bubble
shells may be brittle and inflexible.  This is undesirable for several reasons.  Firstly, a brittle coating limits the capability of the bubble to expand and collapse.  As the bubble encounters different pressure regions within the body (e.g., moving
from the venous system into the arteries upon circulation through the heart) a brittle shell may break and the gas will be lost.  This limits the effective period of time for which useful contrast can be obtained in vivo from the bubbles contrast agents. Also such brittle, broken fragments can be potentially toxic.  Additionally the inflexible nature of brittle coatings such as albumin, and stiff resulting bubbles make it extremely difficult to measure pressure in vivo.


Quay published application WO 93/05819 discloses that gases with high Q numbers are ideal for forming stable gases, but the disclosure is limited to stable gases, rather than their stabilization and encapsulation, as in the present invention.  In
a preferred embodiment described on page 31, sorbitol is used to increase viscosity, which in turn is said to extend the life of a microbubble in solution.  Also, it is not an essential requirement of the present invention that the gas involved have a
certain Q number or diffusibility factor.


Lanza et al. published application WO 93/20802 discloses acoustically reflective oligolamellar liposomes, which are multilamellar liposomes with increased aqueous space between bilayers or have liposomes nested within bilayers in a nonconcentric
fashion, and thus contain internally separated bilayers.  Their use as ultrasonic contrast agents to enhance ultrasonic imaging, and in monitoring a drug delivered in a liposome administered to a patient, is also described.


D'Arrigo U.S.  Pat.  Nos.  4,684,479 and 5,215,680 disclose gas-in-liquid emulsions and lipid-coated microbubbles, respectively.


In accordance with the present invention it has been discovered that stabilized gas filled microspheres are extremely effective, non-toxic contrast agents for MRI.


SUMMARY OF THE INVENTION


The present invention is directed to a contrast medium useful for magnetic resonance imaging, said contrast medium comprising stabilized gas filled microspheres, wherein the gas is a biocompatible gas, e.g., nitrogen or perfluoropropane, but may
also be derived from a gaseous precursor, e.g., perfluorooctylbromide, and the microspheres are stabilized by being formed from a stabilizing compound, e.g., a biocompatible lipid or polymer.  The present invention may be carried out, often with
considerable attendant advantage, by using gaseous precursors to form the gas of the gas filled microspheres.  These gaseous precursors may be activated by a number of factors, but preferably are temperature activated.  Such a gaseous precursor is a
compound which, at a selected activation or transition temperature, changes phases from a liquid to a gas.  Activation thus takes place by increasing the temperature of the compound from a point below, to a point above the activation or transition
temperature The lipid may be in the form of a monolayer or bilayer, and the mono- or bilayer lipids may be used to form a series of concentric mono- or bilayers.  Thus, the lipid may be used to form a unilamellar liposome (comprised of one monolayer or
bilayer lipid), an oligolamellar liposome (comprised of two or three monolayer or bilayer lipids) or a multilamellar liposome (comprised of more than three monolayer or bilayer lipids).  Preferably, the biocompatible lipid comprises a phospholipid. 
Optionally, the contrast medium may include paramagnetic and/or superparamagnetic contrast agents, preferably encapsulated by the microspheres.  Also, optionally, the contrast medium may further comprise a liquid fluorocarbon compound, e.g., a
perfluorocarbon, to further stabilize the microspheres.  Preferably the fluorocarbon liquid is encapsulated by the microspheres.


The present invention also concerns a method for preparing stabilized gas or gaseous precursor filled lipid based microspheres for use as a magnetic resonance imaging contrast medium, comprising the step of agitating an aqueous suspension of the
lipid (that is, the lipid stabilizing compound), in the presence of a gas or gasesous precursor, resulting in gas or gaseous precursor filled microspheres.  Desirably, the agitation step is carried out at a temperature below the gel to liquid crystalline
phase transition temperature of the lipid in order to achieve a preferred end product.


Where a gaseous precursor is used, the gaseous precursor filled microsphere composition is generally maintained at a temperature at which the gaseous precursor is liquid until administration to the patient.  At the time of administration the
temperature may, if desired, be raised to activate the gaseous precursor to form a gas and the resultant gas filled microsphere then administered to the patient.  Alternatively, the gaseous precursor filled microspheres may, if desired, be administered
without raising the temperature, and the gaseous precursor allowed to form a gas as a result of the temperature of the patient.  The composition may be agitated, if necessary, prior to administration.


The present invention further pertains to a method of providing an image of an internal region of a patient, especially an image of the vasculature (including the cardiovascular region), particularly during perfusion, and of the gastrointestinal
region of said patient, said method comprising (i) administering to the patient the foregoing contrast medium, and (ii) scanning the patient using magnetic resonance imaging to obtain visible images of said region.


Finally, the present invention also encompasses a method for diagnosing the presence of diseased tissue in a patient, especially in the vasculature (including the cardiovascular region), particularly during perfusion; and in the gastrointestinal
region of said patient, said method comprising (i) administering to the patient the foregoing contrast medium, and (ii) scanning the patient using magnetic resonance imaging to obtain visible images of any diseased tissue in the region.


These and other aspects of the invention will become more apparent from the following detailed description when taken in conjunction with the following drawings. 

BRIEF DESCRIPTION OF THE FIGURES


FIGS. 1A and B are photomicrographs of stabilized gas filled microspheres having an approximate mean diameter of 10 microns.


FIG. 2 is a diagrammatic representation of an apparatus for filtering and/or dispensing an MRI contrast medium comprising stabilized gas filled microspheres of the present invention.


FIG. 3 is an exploded view of a portion of the apparatus of FIG. 2.


FIG. 4 is a graphic representation of the effect of gas filled microsphere diameter on the domain of magnetization surrounding said microsphere.  The domain of magnetization (i.e., domain of magnetic susceptibility) is shown by the region
traversed by the arrows.  As is shown in the figure, the susceptibility effect or magnetic domain caused by the microsphere has a relationship to microsphere diameter.  Microsphere diameter decreases with increasing pressure, causing a proportionately
greater decrease in the domain of magnetic susceptibility.  For elastic pressure sensitive microspheres, this phenomenon of microsphere diameter/susceptibility dynamics can be utilized to non-invasively assess pressure in vivo by MRI.


FIG. 5 is a graphic representation of the relationship between 1/T.sub.2 (in seconds) versus gas concentrations for several different gases.  Samples of gas filled microspheres were prepared using different gases.  The gas filled microspheres
were then scanned by magnetic resonance using a Brinker Biospec II 4.7 Tesla scanner (Bruker, Billerica, Mass.).  T2 measurements were performed by scanning the samples with Spin Echo Sequences TR=800 msec and TE=30, 45, 60, 75 and 90 msec and gradient
echo sequences for signal intensity measurements with TR=60 msec, TE=8 with a 40% flip.


FIG. 5A shows the 1/T.sub.2 versus gas concentrations for perfluoropropane (PFP), neon, oxygen, air, and nitrogen gas.


FIG. 5B shows the 1/T.sub.2 versus gas concentrations for xenon, argon, sulfur hexafluoride (SHF), and perfluorobutane (PFB) gas.


FIG. 6 provides a diagram of the effect of pressure on gas filled microsphere size.


FIG. 7 is a graph showing the effect of pressure on 1/T2 (in seconds) of gas filled microspheres containing 2.5% by volume of neon, using ascending and decending pressures of 0, 50, 100, 150, 200, 250, and 300 mm Hg.


FIG. 8 is a graph showing the effect of pressure on 1/T2 (in seconds) of gas filled microspheres containing 2.5% by volume of perfluoropropane (PFP), using ascending and decending pressures of 0, 50, 100, 150, 200, 250, and 300 mm Hg.


FIG. 9 is a graphical representation of the effect of pressure on signal intensity of a gradient echo pulse sequence using nitrogen gas filled microspheres, applying ascending and decending pressures of 0, 50, 100, 150, 200, 250, and 300 mm Hg.


DETAILED DESCRIPTION OF THE INVENTION


The present invention is directed, inter alia, to stabilized gas filled microspheres.  While not intending to be bound by any particular theory of operation, the present invention is believed to rely, at least in part, on the fact that gas,
liquid and solid phases have different magnetic susceptibilities.  At the interface of gas and water, for example, the magnetic domains are altered and this results in dephasing of the spins of, e.g., the hydrogen nuclei.  In imaging this is seen as a
decrease in signal intensity adjacent to the gas/water interface.  This effect is more marked on T2 weighted images and most prominent on gradient echo pulse sequences.  The effect is increased by using narrow bandwidth extended read-out pulse sequences. The longer the echo time on a gradient echo pulse sequence, the greater the effect (i.e., the greater the degree and size of signal loss).


The stabilized gas filled microspheres of the present invention are believed to rely on this phase magnetic susceptibility difference, as well as on the other characteristics described in more detail herein, to provide high performance level
magnetic resonance imaging contrast agents.  The microspheres are formed from, i.e., created out of, a matrix of stabilizing compounds which permit the gas filled microspheres to be established and thereafter retain their size and shape for the period of
time required to be useful in magnetic resonance imaging.  These stabilizing compounds are most typically those which have a hydrophobic/hydrophilic character which allows them to form monolayers or bilayers, etc., and microspheres, in the presence of
water.  Thus, water, saline or some other water-based medium, often referred to hereafter as a diluent, is generally an aspect of the stabilized gas filled microsphere contrast medium of the present invention.


The stabilizing compound may, in fact, be a mixture of compounds which contribute various desirable attributes to the stabilized microspheres.  For example, compounds which assist in the dissolution or dispersion of the fundamental stabilizing
compound have been found advantageous.  A further element of the stabilized microspheres is a gas, which can be a gas at the time the microspheres are made, or can be a gaseous precursor which, responsive to an activating factor, such as temperature, is
transformed from the liquid phase to the gas phase.  The various aspects of the stabilized gas filled contrast media of the present invention will now be described, starting with the gases which comprise the microspheres.


Gases and Gaseous Precursors


The microspheres of the invention encapsulate a gas and/or gaseous precursor.  The term "gas filled and/or gaseous precursor filled", as used herein, means that the microspheres to which the present invention is directed, have an interior volume
that is comprised of at least about 10% gas and gasesous precursor, preferably at least about 25% gas and gaseous precursor, more preferably at least about 50% gas and gaseous precursor, even more preferably at least about 75% gas and gaseous precursor,
and most preferably at least about 90% gas and gaseous precursor.  In use, where the presence of gas is important, it is preferred that the interior microsphere volume comprise at least about 10% gas, preferably at least about 25%, 50%, 75%, and most
preferably at least about 90% gas.


Any of the various biocompatible gases and gaseous precursors may be employed in the gas and gaseous precursor filled microspheres of the present invention Such gases include, for example, air, nitrogen, carbon dioxide, oxygen, argon, fluorine,
xenon, neon, helium, or any and all combinations thereof.  Of such gases, nitrogen is preferred.  Likewise, various fluorinated gaseous compounds, such as various perfluorocarbon, hydrofluorocarbon, and sulfur hexafluoride gases may be utilized in the
preparation of the gas filled microspheres.  Also, the gases discussed in Quay, published application WO 93/05819, including the high "IQ" factor gases described therein, the disclosures of which are hereby incorporated herein by reference in their
entirety, may be employed.  Further, paramagnetic gases or gases such as .sup.17 O may be used.  Of all of the gases, perfluorocarbons and sulfur hexafluoride are preferred.  Suitable perfluorcarbon gases include, for example, perfluorobutane,
perfluorocyclobutane, perfluoromethane, perfluoroethane, perfluoropropane, and perfluoropentane, most preferably perfluoropropane.  Also preferred are a mixture of different types of gases, such as a perfluorocarbon gas and another type of gas such as
oxygen, etc. Indeed, it is believed that a combination of gases may be particularly useful in magnetic resonance imaging applications.  Table 3 in the Examples below shows the R2 (1/T2/mmol/L.sec-1) for different gases in lipid microspheres (the higher
the R2 relaxation values, the more effective as an MRI contrast medium).  As Table 3 shows, there may be dramatic differences in the relaxivity of different gas filled microspheres.


Notwithstanding the requirement that the gas and gaseous precursor filled microspheres be made from stabilizing compounds, it is preferred that a rather highly stable gas be utilized as well.  By highly stable gas is meant a gas selected from
those gases which will have low (limited) solubility and diffusability in aqueous media.  Gases such as perfluorocarbons are less diffusible and relatively insoluble and as such are easier to stabilize into the form of bubbles in aqueous media.


The use of gaseous precursors is an optional embodiment of the present invention.  In particular, perfluorocarbons have been found to be suitable for use as gaseous precursors.  As the artisan will appreciate, a given perfluorocarbon may be used
as a gaseous precursor, i.e., in the liquid state when the microspheres of the present invention are first made, or may be used as a gas directly, i.e., in the gas state, to make the gas and gaseous precursor filled microspheres.  Whether such a
perfluorocarbon is a gas or liquid depends, of course, on its liquid/gas phase transition temperature, or boiling point.  For example, one of the more preferred perfluorocarbons is perfluoropentane, which has a liquid/gas phase transition temperature or
boiling point of 27.degree.  C., which means that it will be a liquid at ordinary room temperature, but will become a gas in the environment of the human body, where the temperature will be above its liquid/gas phase transition temperature or boiling
point.  Thus, under normal circumstance, perfluoropentane is a gaseous precursor.  As further examples, there is perfluorobutane and perflurohexane, the next closest homologs of perfluoropentane.  The liquid/gas phase transition temperature of
perfluorobutane is 4.degree.  C. and that of perfluorohexane is 57.degree.  C., making the former potentially a gaseous precursor, but generally more useful as a gas, while the latter would generally be a gaseous precursor, except under unusual
circumstances, because of its high boiling point.


Another aspect of the present invention is the use of a fluorinated compound, especially a perfluorocarbon compound, which will be in the liquid state at the temperature of use of the microspheres of the present invention, to assist or enhance
the stability of said gas and gaseous precursor filled microspheres.  Such fluorinated compounds include various liquid fluorinated compounds, such as fluorinated surfactants manufactured by the DuPont Company (Wilmington, Del.), e.g., Zonyl.TM., as well
as liquid perfluorocarbons.  Preferably the fluorinated compounds are perfluorocarbons.  Suitable perfluorocarbons useful as additional stabilizing agents include perfluorooctylbromide (PFOB), perfluorodecalin, perfluorododecalin, perfluorooctyliodide,
perfluorotripropylamine, and perfluorotributylamine.  In general, perfluorocarbons over six carbon atoms in length will not be gaseous, i.e., in the gas state, but rather will be liquids, i.e., in the liquid state, at normal human body temperature. 
These compounds may, however, additionally be utilized in preparing the stabilized gas and gaseous precursor filled microspheres used in the present invention.  Preferably this perfluorocarbon is perfluorooctylbromide or perfluorohexane, which is in the
liquid state at room temperature.  The gas which is present may be, e.g., nitrogen or perfluoropropane, or may be derived from a gaseous precursor, which may also be a perfluorocarbon, e.g., perfluoropentane.  In that case, the microspheres of the
present invention would be prepared from a mixture of perfluorocarbons, which for the examples given, would be perfluoropropane (gas) or perfluoropentane (gaseous precursor) and perfluorooctylbromide (liquid).  Although not intending to be bound by any
theory, it is believed that the liquid fluorinated fluorinated compound is situated at the interface between the gas and the membrane surface of the microsphere.  There is thus formed a further stabilizing layer of liquid fluorinated compound on the
internal surface of the stabilizing compound, e.g., a biocompatible lipid used to form the microsphere, and this perfluorocarbon layer also serves the purpose of preventing the gas from diffusing through the microsphere membrane.  A gaseous precursor,
within the context of the present invention, is a liquid at the temperature of manufacture and/or storage, but becomes a gas at least at or during the time of use.


Thus, it has been discovered that a liquid fluorinated compound, such as a perfluorocarbon, when combined with a gas or gasesous precursor ordinarily used to make the microspheres of the present invention, may confer an added degree of stability
not otherwise obtainable with the gas or gaseous precursor alone.  Thus, it is within the scope of the present invention to utilize a gas or gaseous precursor, such as a perfluorocarbon gaseous precursor, e.g., perfluoropentane, together with a
perfluorocarbon which remains liquid after administration to a patient, i.e., whose liquid to gas phase transition temperature is above the body temperature of the patient, e.g., perfluoroctylbromide.


Any biocompatible gas or gaseous precursor may be used to form the stabilized gas and gaseous precursor filled microspheres.  By "biocompatible" is meant a gas or gaseous precursor which, when introduced into the tissues of a human patient, will
not result in any degree of unacceptable toxicity, including allergenic responses and disease states, and preferably are inert.  Such a gas or gaseous precursor should also be suitable for making gas and gaseous precursor filled microspheres, as
described herein.


The size of the gas or gaseous precursor filled microspheres becomes stabilized when the stabilizing compounds described herein are employed; and the size of the microspheres can then be adjusted for the particular intended MRI end use.  For
example, magnetic resonance imaging of the vasculature may require microspheres that are no larger that about 30.mu.  in diameter, and that are preferably smaller, e.g., no larger than about 12.mu.  in diameter.  The size of the gas filled microspheres
can be adjusted, if desired, by a variety of procedures including microemulsification, vortexing, extrusion, filtration, sonication, homogenization, repeated freezing and thawing cycles, extrusion under pressure through pores of defined size, and similar
methods.


For intravascular use the microspheres are generally under 30.mu.  in mean diameter, and are preferably under about 12.mu.  in mean diameter.  For targeted intravascular use, e.g., to bind to a certain tissue such as a tumor, the microspheres can
be appreciably under a micron, even under 100 nm diameter.  For enteric, i.e., gastrointestinal use the microspheres can be much larger, e.g., up to a millimeter in size, but microspheres between 20.mu.  and 100.mu.  in mean diameter are preferred.


As noted above, the embodiments of the present invention may also include, with respect to their preparation, formation and use, gaseous precursors that can be activated by temperature.  Further below is set out a table listing a series of
gaseous precursors which undergo phase transitions from liquid to gaseous states at relatively close to normal body temperature (37.degree.  C.) or below, and the size of the emulsified droplets that would be required to form a microbubble of a maximum
size of 10 microns.


 TABLE I  ______________________________________ Physical Characteristics of Gaseous Precursors and  Diameter of Emulsified Droplet to Form a 10 .mu.m Microsphere*  Diameter (.mu.m) of  emulsified droplet  Molecular  Boiling Point to make 10
micron  Compound  Weight (.degree. C.)  Density  microsphere  ______________________________________ perfluoro  288.04 57.73 1.7326 2.9  pentane  1- 76.11 32.5 6.7789 1.2  fluorobutane  2-methyl  72.15 27.8 0.6201 2.6  butane  (isopentane)  2-methyl 1- 
70.13 31.2 0.6504 2.5  butene  2-methyl-2-  70.13 38.6 0.6623 2.5  butene  1-butene-3-  66.10 34.0 0.6801 2.4  yne-2-methyl  3-methyl-1-  68.12 29.5 0.6660 2.5  butyne  octafluoro  200.04 -5.8 1.48 2.8  cyclobutane  decafluoro  238.04 -2 1.517 3.0 
butane  hexafluoro  138.01 -78.1 1.607 2.7  ethane  ______________________________________ *Source: Chemical Rubber Company Handbook of Chemistry and Physics, Rober  C. Weast and David R. Lide, eds., CRC Press, Inc. Boca Raton, Florida  (1989-1990).


There is also set out below a list composed of potential gaseous precursors that may be used to form microspheres of defined size.  However, the list is not intended to be limiting, since it is possible to use other gaseous precursors for that
purpose.  In fact, for a variety of different applications, virtually any liquid can be used to make gaseous precursors so long as it is capable of undergoing a phase transition to the gas phase upon passing through the appropriate temperature, so that
at least at some point in use it provides a gas.  Suitable gaseous precursors for use in the present invention are the following: hexafluoro acetone, isopropyl acetylene, allene, tetrafluoroallene, boron trifluoride, isobutane, 1,2-butadiene,
2,3-butadiene, 1,3-butadiene, 1,2,3-trichloro-2-fluoro-1,3-butadiene, 2-methyl-1,3-butadiene, hexafluoro-1,3-butadiene, butadiyne, 1-fluoro-butane, 2-methyl-butane, decafluorobutane, 1-butene, 2-butene, 2-methyl-1-butene, 3-methyl-1-butene,
perfluoro-1-butene, perfluoro-2-butene, 4-phenyl-3-butene-2-one, 2-methyl-1-butene-3-yne, butyl nitrate, 1-butyne, 2-butyne, 2-chloro-1,1,1,4,4,4-hexafluorobutyne, 3-methyl-1-butyne, perfluoro-2-butyne, 2-bromobutyraldehyde, carbonyl sulfide,
crotononitrile, cyclobutane, methyl-cyclobutane, octafluoro-cyclobutane, perfluorocyclobutene, 3-chlorocyclopentene, octafluorocyclopentene-cyclopropane, 1,2-dimethyl-cyclopropane, 1,1-dimethylcyclopropane, 1,2-dimethyl-cyclopropane, ethylcyclopropane,
methylcyclopropane, diacetylene, 3-ethyl-3-methyl diaziridine, 1,1,1-trifluorodiazoethane, dimethyl amine, hexafluorodimethylamine, dimethylethylamine, bis(dimethylphosphine)amine, perfluorohexane, 2,3-dimethyl-2-norbornane, perfluorodimethylamine,
dimethyloxonium chloride, 1,3-dioxolane-2-one, 4-methyl-1,1,1,2-tetrafluoroethane, 1,1,1-trifluoroethane, 1,1,2,2-tetrafluoroethane, 1,1,2-trichloro-1,2,2-trifluoroethane, 1,1-dichloroethane, 1,1-dichloro-1,2,2,2-tetrafluoroethane, 1,2-difluoroethane,
1-chloro-1,1,2,2,2-pentafluoroethane, 2-chloro-1,1-difluoroethane, 1,1-dichloro-2-fluoroethane, 1-chloro-1,1,2,2-tetrafluoroethane, 2-chloro-1,1-difluoroethane, chloroethane, chloropentafluoroethane, dichlorotrifluoroethane, fluoroethane,
hexafluoroethane, nitropentafluoroethane, nitrosopentafluoroethane, perfluoroethylamine, ethyl vinyl ether, 1,1-dichloroethane, 1,1-dichloro-1,2-difluoroethane, 1,2-difluoroethane, methane, trifluoromethanesulfonylchloride,
trifluoromethanesulfonylfluoride, bromodifluoronitrosomethane, bromofluoromethane, bromochlorofluoromethane, bromotrifluoromethane, chlorodifluoronitromethane, chlorodinitromethane, chlorofluoromethane, chlorotrifluoromethane, chlorodifluoromethane,
dibromodifluoromethane, dichlorodifluoromethane, dichlorofluoromethane, difluoromethane, difluoroiodomethane, disilanomethane, fluoromethane, iodomethane, iodotrifluoromethane, nitrotrifluoromethane, nitrosotrifluoromethane, tetrafluoromethane,
trichlorofluoromethane, trifluoromethane, 2-methylbutane, methyl ether, methyl isopropyl ether, methyllactate, methylnitrite, methylsulfide, methyl vinyl ether, neon, neopentane, nitrogen (N.sub.2), nitrous oxide, 1,2,3-nonadecane-tricarboxylic
acid-2-hydroxytrimethylester, 1-nonene-3-yne, oxygen (O.sub.2), 1,4-pentadiene,  n-pentane, perfluoropentane, 4-amino-4-methylpentan-2-one, 1-pentene, 2-pentene (cis), 2-pentene (trans), 3-bromopent-1-ene, perfluoropent-1-ene, tetrachlorophthalic acid,
2,3,6-trimethylpiperidine, propane, 1,1,1,2,2,3-hexafluoropropane, 1,2-epoxypropane, 2,2-difluoropropane, 2-aminopropane, 2-chloropropane, heptafluoro-1-nitropropane, heptafluoro-1-nitrosopropane, perfluoropropane, propene, hexafluoropropane,
1,1,1,2,3,3-hexafluoro-2,3 dichloropropane, 1-chloropropane, chloropropane-(trans), 2-chloropropane, 3-fluoropropane, propyne, 3,3,3-trifluoropropyne, 3-fluorostyrene, sulfur hexafluoride, sulfur (di)-decafluoride(S.sub.2 F.sub.10), 2,4-diaminotoluene,
trifluoroacetonitrile, trifluoromethyl peroxide, trifluoromethyl sulfide, tungsten hexafluoride, vinyl acetylene, vinyl ether, and xenon.


The perfluorocarbons, as already indicated, are preferred for use as the gas or gaseous precursors, as well as additional stabilizing components.  Included in such perfluorocarbon compositions are saturated perfluorocarbons, unsaturated
perfluorocarbons, and cyclic perfluorocarbons.  The saturated perfluorocarbons, which are usually preferred, have the formula C.sub.n F.sub.2n+2, where n is from 1 to 12, preferably 2 to 10, more preferably 4 to 8, and most preferably 5.  Examples of
suitable saturated perfluorocarbons are the following: tetrafluoromethane, hexafluoroethane, octafluoropropane, decafluorobutane, dodecafluoropentane, perfluorohexane, and perfluoroheptane.  Cyclic perfluorocarbons, which have the formula C.sub.n
F.sub.2n, where n is from 3 to 8, preferably 3 to 6, may also be preferred, and include, e.g., hexafluorocyclopropane, octafluorocyclobutane, and decafluorocyclopentane.


It is part of the present invention to optimize the utility of the microspheres by using gases of limited solubility.  By limited solubility, is meant the ability of the gas to diffuse out of the microspheres by virtue of its solubility in the
surrounding aqueous medium.  A greater solubility in the aqueous medium imposes a gradient with the gas in the microsphere such that the gas will have a tendency to diffuse out of said microsphere.  A lesser solubility in the aqueous milieu, will, on the
other hand, decrease or eliminate the gradient between the microsphere and the interface such that the diffusion of the gas out of the microsphere will be impeded.  Preferably, the gas entrapped in the microsphere has a solubility less than that of
oxygen, i.e., 1 part gas in 32 parts water.  See Matheson Gas Data Book, 1966, Matheson Company Inc.  More preferably, the gas entrapped in the microsphere possesses a solubility in water less than that of air; and even more preferably, the gas entrapped
in the microsphere possesses a solubility in water less than that of nitrogen.


Stabilizing Compounds


One or more stabilizing compounds are employed to form the microspheres, and to assure continued encapsulation of the gases or gaseous precursors.  Even for relatively insoluble, non-diffusible gases such as perfluoropropane or sulfur
hexafluoride, improved microsphere preparations are obtained when one or more stabilizing compounds are utilized in the formation of the gas and gaseous precursor filled microspheres.  These compounds maintain the stability and the integrity of the
microspheres with regard to their size, shape and/or other attributes.


The terms "stable" or "stabilized", as used herein, means that the microspheres are substantially resistant to degradation, i.e., are resistant to the loss of microsphere structure or encapsulated gas or gaseous precursor for a useful period of
time.  Typically, the microspheres of the invention have a good shelf life, often retaining at least about 90 percent by volume of its original structure for a period of at least about two or three weeks under normal ambient conditions, although it is
preferred that this period be at least a month, more at least preferably two months, even more preferably at least six months, still more preferably eighteen months, and most preferably three years.  Thus, the gas and gaseous precursor filled
microspheres typically have a good shelf life, sometimes even under adverse conditions, such as temperatures and pressures which are above or below those experienced under normal ambient conditions.


The stability of the microspheres of the present invention is attributable, at least in part, to the materials from which said microspheres are made, and it is often not necessary to employ additional stabilizing additives, although it is
optional and often preferred to do so; and such additional stabilizing agents and their characteristics are explained in more detail herein.  The materials from which the microspheres used in the present invention are constructed are preferably
biocompatible lipid or polymer materials, and of these, the biocompatible lipids are especially preferred.  In addition, because of the ease of formulation, i.e., the ability to produce the microspheres just prior to administration, these microspheres
may be conveniently made on site.


The lipids and polymers employed in preparing the microspheres of the invention are biocompatible.  By "biocompatible" is meant a lipid or polymer which, when introduced into the tissues of a human patient, will not result in any degree of
unacceptable toxicity, including allergenic responses and disease states.  Preferably the lipids or polymers are inert.


-Biocompatible Lipids


For the biocompatible lipid materials, it is preferred that such lipid materials be what is often referred to as "amphiphilic" in nature (i.e., polar lipid), by which is meant any composition of matter which has, on the one hand, lipophilic, i
e., hydrophobic properties, while on the other hand, and at the same time, having lipophobic, i.e., hydrophilic properties.


Hydrophilic groups may be charged moieties or other groups having an affinity for water.  Natural and synthetic phospholipids are examples of lipids useful in preparing the stabilized microspheres used in the present invention.  They contain
charged phosphate "ahead" groups which are hydrophilic, attached to long hydrocarbon tails, which are hydrophobic.  This structure allows the phospholipids to achieve a single bilayer (unilamellar) arrangement in which all of the water-insoluble
hydrocarbon tails are in contact with one another, leaving the highly charged phosphate head regions free to interact with a polar aqueous environment.  It will be appreciated that a series of concentric bilayers are possible, i.e., oligolamellar and
multilamellar, and such arrangements are also contemplated to be an aspect of the present invention.  The ability to form such bilayer arrangements is one feature of the lipid materials useful in the present invention.


The lipid may alternatively be in the form of a monolayer, and the monolayer lipids may be used to form a single monolayer (unilamellar) arrangement.  Alternatively, the monolayer lipid may be used to form a series of concentric monolayers, i.e.,
oligolamellar or multilamellar, and such arrangements are also considered to be within the scope of the invention.


It has also been found advantageous to achieving the stabilized microspheres of the present invention that they be prepared at a temperature below the gel to liquid crystalline phase transition temperature of a lipid used as the stabilizing
compound.  This phase transition temperature is the temperature at which a lipid bilayer will convert from a gel state to a liquid crystalline state.  See, for example, Chapman et al., J. Biol.  Chem. 1974 249, 2512-2521.


It is believed that, generally, the higher the gel state to liquid crystalline state phase transition temperature, the more impermeable the gas and gaseous precursor filled microspheres are at any given temperature.  See Derek Marsh, CRC Handbook
of Lipid Bilayers (CRC Press, Boca Raton, Fla.  1990), at p. 139 for main chain melting transitions of saturated diacyl-sn-glycero-3phosphocholines.  The gel state to liquid crystalline state phase transition temperatures of various lipids will be
readily apparent to those skilled in the art and are described, for example, in Gregoriadis, ed., Liposome Technology, Vol. I, 1-18 (CRC Press, 1984).  The following table lists some of the representative lipids and their phase transition temperatures:


 TABLE 2  ______________________________________ Saturated Diacyl sn-Glycero(3)Phosphocholines:  Main Chain Phase Transition Temperatures  Main Phase  Carbons in Acyl  Transition  Chains Temperature .degree. C. 
______________________________________ 1,2-(12:0) -1.0  1,2-(13:0) 13.7  1,2-(14:0) 23.5  1,2-(15:0) 34.5  1,2-(16:0) 41.4  1,2-(17:0) 48.2  1,2-(18:0) 55.1  1,2-(19:0) 61.8  1,2-(20:0) 64.5  1,2-(21:0) 71.1  1,2-(22:0) 74.0  1,2-(23:0) 79.5  1,2-(24:0)
80.1  ______________________________________ *Derek March, "CRC Handbook of Lipid Bilayers", CRC Press, Boca Raton,  Florida (1990), page 139.


It has been found possible to enhance the stability of the microspheres used in the present invention by incorporating at least a small amount, i.e., about 1 to about 10 mole percent of the total lipid, of a negatively charged lipid into the
lipid from which the gas and gaseous precursor filled microspheres are to be formed.  Suitable negatively charged lipids include, e.g., phosphatidylserine, phosphatidic acid, and fatty acids.  Such negatively charged lipids provide added stability by
counteracting the tendency of the microspheres to rupture by fusing together, i.e., the negatively charged lipids tend to establish a uniform negatively charged layer on the outer surface of the microsphere, which will be repulsed by a similarly charged
outer layer on the other microspheres.  In this way, the microspheres will tend to be prevented from coming into touching proximity with each other, which would often lead to a rupture of the membrane or skin of the respective microspheres and
consolidation of the contacting microspheres into a single, larger microsphere.  A continuation of this process of consolidation will, of course, lead to significant degradation of the microspheres.


The lipid material or other stabilizing compound used to form the microspheres is also preferably flexible, by which is meant, in the context of gas and gaseous precursor filled microspheres, the ability of a structure to alter its shape, for
example, in order to pass through an opening having a size smaller than the microsphere.


In selecting a lipid for preparing the stabilized microspheres used in the present invention, a wide variety of lipids will be found to be suitable for their construction.  Particularly useful are any of the materials or combinations thereof
known to those skilled in the art as suitable for liposome preparation.  The lipids used may be of either natural, synthetic or semi-synthetic origin.


Lipids which may be used to prepare the gas and gaseous precursor filled microspheres used in the present invention include but are not limited to: lipids such as fatty acids, lysolipids, phosphatidylcholine with both saturated and unsaturated
lipids including dioleoylphosphatidylcholine; dimyristoylphosphatidylcholine; dipentadecanoylphosphatidylcholine; dilauroylphosphatidylcholine; dipalmitoylphosphatidylcholine (DPPC); distearoylphosphatidylcholine (DSPC); phosphatidylethanolamines such as
dioleoylphosphatidylethanolamine and dipalmitoylphosphatidylethanolamine (DPPE); phosphatidylserine; phosphatidylglycerol; phosphatidylinositol; sphingolipids such as sphingomyelin; glycolipids such as ganglioside GM1 and GM2; glucolipids; sulfatides;
glycosphingolipids; phosphatidic acids such as dipalymitoylphosphatidic acid (DPPA); palmitic acid; stearic acid; arachidonic acid; oleic acid; lipids bearing polymers such as polyethyleneglycol, i.e., PEGylated lipids, chitin, hyaluronic acid or
polyvinylpyrrolidone; lipids bearing sulfonated mono-, di-, oligo- or polysaccharides; cholesterol, cholesterol sulfate and cholesterol hemisuccinate; tocopherol hemisuccinate; lipids with ether and ester-linked fatty acids; polymerized lipids (a wide
variety of which are well known in the art); diacetyl phosphate; dicetyl phosphate; stearylamine; cardiolipin; phospholipids with short chain fatty acids of 6-8 carbons in length; synthetic phospholipids with asymmetric acyl chains (e.g., with one acyl
chain of 6 carbons and another acyl chain of 12 carbons); ceramides; non-ionic liposomes including niosomes such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohols, polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty
acid esters, glycerol polyethylene glycol oxystearate, glycerol polyethylene glycol ricinoleate, ethoxylated soybean sterols, ethoxylated castor oil, polyoxyethylene-polyoxypropylene polymers, and polyoxyethylene fatty acid stearates; sterol aliphatic
acid esters including cholesterol sulfate, cholesterol butyrate, cholesterol iso-butyrate, cholesterol palmitate, cholesterol stearate, lanosterol acetate, ergosterol palmitate, and phytosterol n-butyrate; sterol esters of sugar acids including
cholesterol glucuroneide, lanosterol glucuronide, 7-dehydrocholesterol glucuronide, ergosterol glucuronide, cholesterol gluconate, lanosterol gluconate, and ergosterol gluconate; esters of sugar acids and alcohols including lauryl glucuronide, stearoyl
glucuronide, myristoyl glucuronide, lauryl gluconate, myristoyl gluconate, and stearoyl gluconate; esters of sugars and aliphatic acids including sucrose laurate, fructose laurate, sucrose palmitate, sucrose stearate, glucuronic acid, gluconic acid,
accharic acid, and polyuronic acid; saponins including  sarsasapogenin, smilagenin, hederagenin, oleanolic acid, and digitoxigenin; glycerol dilaurate, glycerol trilaurate, glycerol dipalmitate, glycerol and glycerol esters including glycerol
tripalmitate, glycerol distearate, glycerol tristearate, glycerol dimyristate, glycerol trimyristate; longchain alcohols including n-decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, and n-octadecyl alcohol;
6-(5-cholesten-3.beta.-yloxy)-1-thio-.beta.-D-galactopyranoside; digalactosyldiglyceride; 6-(5-cholesten-3.beta.-yloxy)hexyl-6-amino-6-deoxy-1-thio-.beta.-D-galacto pyranoside; 6-(5-cholesten-3.beta.-yloxy)hexyl-6-amino-6-deoxyl-1-thio-.alpha.-D-manno
pyranoside; 12-(((7'-diethylaminocoumarin-3-yl)carbonyl)methylamino)-octadecanoic acid; N-[12-(((7'-diethylaminocoumarin-3-yl)carbonyl)methyl-amino) octadecanoyl]-2-aminopalmitic acid; cholesteryl)4'-trimethylammonio)butanoate;
N-succinyldioleoylphosphatidylethanolamine; 1,2-dioleoyl-sn-glycerol; 1,2-dipalmitoyl-sn-3-succinylglycerol; 1,3-dipalmitoyl-2-succinylglycerol; 1-hexadecyl-2-palmitoyl-glycerophosphoethanolamine and palmitoylhomocysteine, and/or combinations thereof.


If desired, a variety of cationic lipids such as DOTMA, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoium chloride; DOTAP, 1,2-dioleoyloxy-3-(trimethylammonio)propane; and DOTB, 1,2-dioleoyl-3-(4'-trimethyl-ammonio)butanoyl-sn-glycerol may be
used.  In general the molar ratio of cationic lipid to non-cationic lipid in the liposome may be, for example, 1:1000, 1:100, preferably, between 2:1 to 1:10, more preferably in the range between 1:1 to 1:2.5 and most preferably 1:1 (ratio of mole amount
cationic lipid to mole amount non-cationic lipid, e.g., DPPC).  A wide variety of lipids may comprise the non-cationic lipid when cationic lipid is used to construct the microsphere.  Preferably, this non-cationic lipid is dipalmitoylphosphatidylcholine,
dipalmitoylphosphatidylethanolamine or dioleoylphosphatidylethanolamine.  In lieu of cationic lipids as described above, lipids bearing cationic polymers such as polylysine or polyarginine, as well as alkyl phosphonates, alkyl phosphinates, and alkyl
phosphites, may also be used to construct the microspheres.


The most preferred lipids are phospholipids, preferably DPPC, DPPE, DPPA and DSPC, and most preferably DPPC.


In addition, examples of saturated and unsaturated fatty acids that may be used to prepare the stabilized microspheres used in the present invention, in the form of gas and gaseous precursor filled mixed micelles, may include molecules that may
contain preferably between 12 carbon atoms and 22 carbon atoms in either linear or branched form.  Hydrocarbon groups consisting of isoprenoid units and/or prenyl groups can be used as well.  Examples of saturated fatty acids that are suitable include,
but are not limited to, lauric, myristic, palmitic, and stearic acids; examples of unsaturated fatty acids that may be used are, but are not limited to, lauroleic, physeteric, myristoleic, palmitoleic, petroselinic, and oleic acids; examples of branched
fatty acids that may be used are, but are not limited to, isolauric, isomyristic, isopalmitic, and isostearic acids.  In addition, to the saturated and unsaturated groups, gas and gaseous precursor filled mixed micelles can also be composed of 5 carbon
isoprenoid and prenyl groups.


-Biocompatible Polymers


The biocompatible polymers useful as stabilizing compounds for preparing the gas and gaseous precursor filled microspheres used in the present invention can be of either natural, semi-synthetic (modified natural) or synthetic origin.  As used
herein, the term polymer denotes a compound comprised of two or more repeating monomeric units, and preferably 10 or more repeating monomeric units.  The phrase semi-synthetic polymer (or modified natural polymer), as employed herein, denotes a natural
polymer that has been chemically modified in some fashion.  Exemplary natural polymers suitable for use in the present invention include naturally occurring polysaccharides.  Such polysaccharides include, for example, arabinans, fructans, fucans,
galactans, galacturonans, glucans, mannans, xylans (such as, for example, inulin), levan, fucoidan, carrageenan, galatocarolose, pectic acid, pectin, amylose, pullulan, glycogen, amylopectin, cellulose, dextran, pustulan, chitin, agarose, keratan,
chondroitan, dermatan, hyaluronic acid, alginic acid, xanthan gum, starch and various other natural homopolymer or heteropolymers such as those containing one or more of the following aldoses, ketoses, acids or amines: erythrose, threose, ribose,
arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, mannitol, sorbitol, lactose, sucrose, trehalose, maltose, cellobiose, glycine, serine,
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, glucuronic acid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, and neuraminic acid, and
naturally occurring derivatives thereof.  Exemplary semi-synthetic polymers include carboxymethylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, and methoxycellulose.  Exemplary synthetic polymers suitable for use in the
present invention include polyethylenes (such as, for example, polyethylene glycol, polyoxyethylene, and polyethylene terephthlate), polypropylenes (such as, for example, polypropylene glycol), polyurethanes (such as, for example, polyvinyl alcohol
(PVA), polyvinylchloride and polyvinylpyrrolidone), polyamides including nylon, polystyrene, polylactic acids, fluorinated hydrocarbons, fluorinated carbons (such as, for example, polytetrafluoroethylene), and polymethylmethacrylate, and derivatives
thereof.  Methods for the preparation of such polymer-based microspheres will be readily apparent to those skilled in the art, once armed with the present disclosure, when the present disclosure is coupled with information known in the art, such as that
described and referred to in Unger, U.S.  Pat.  No. 5,205,290, the disclosures of which are hereby incorporated herein by reference, in their entirety.


Preferably, when intended to be used in the gastrointestinal tract, the polymer employed is one which has a relatively high water binding capacity.  When used, for example, in the gastrointestinal region, a polymer with a high water binding
capacity binds a large amount of free water, enabling the polymer to carry a large volume of liquid through the gastrointestinal tract, thereby filling and distending the tract.  The filled and distended gastrointestinal tract permits a clearer picture
of the region.  In addition, where imaging of the gastrointestinal region is desired, preferably the polymer employed is also one which is not substantially degraded within and absorbed from the gastrointestinal region.  Minimization of metabolism and
absorption within the gastrointestinal tract is preferable, so as to avoid the removal of the contrast agent from the tract as well as avoid the formation of gas within the tract as a result of this degradation.  Moreover, particularly where
gastrointestinal usage is contemplated, polymers are preferably such that they are capable of displacing air and minimizing the formation of large air bubbles within the polymer composition.


Particularly preferred embodiments of the present invention include microspheres wherein the stabilizing compound from which the stabilized gas and gaseous precursor filled microspheres are formed comprises three components, (1) a neutral (e.g.,
nonionic or zwitterionic) lipid, (2) a negatively charged lipid, and (3) a lipid bearing a hydrophilic polymer.  Preferably, the amount of said negatively charged lipid will be greater than 1 mole percent of total lipid present, and the amount of lipid
bearing a hydrophilic polymer will be greater than 1 mole percent of total lipid present.  It is also preferred that said negatively charged lipid be a phosphatidic acid.  The lipid bearing a hydrophilic polymer will desirably be a lipid covalently bound
to said polymer, and said polymer will preferably have a weight average molecular weight of from about 400 to about 100,000.  Said hydrophilic polymer is preferably selected from the group consisting of polyethyleneglycol, polypropyleneglycol,
polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.  The PEG or other polymer may be bound to the DPPE or other lipid through a covalent linkage, such as through an amide, carbamate or amine linkage.  Alternatively, ester, ether,
thioester, thioamide or disulfide (thioester) linkages may be used with the PEG or other polymer to bind the polymer to, for example, cholesterol or other phospholipids.  Where the hydrophilic polymer is polyethyleneglycol, a lipid bearing such a polymer
will be said to be "PEGylated", which has reference to the abbreviation for polyethyleneglycol: "PEG".  Said lipid bearing a hydrophilic polymer is preferably dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000, i.e., a
dipalmitoylphosphatidylethanolamine lipid having a polyethyleneglycol polymer of a mean weight average molecular weight of about 5000 attached thereto (DPPE-PEG5000); or distearoyl-phosphatidylethanolamine-polyethyleneglycol 5000.


Preferred embodiments of the microsphere contemplated by the present invention would include, e.g., 77.5 mole percent dipalmitoylphophatidylcholine (DPPC), with 12.5 mole percent of dipalmitoylphosphatidic acid (DPPA), and with 10 mole percent of
dipalmitoylphosphatidylethanolamine-polyethyleneglycol-5000 (DPPE/PEG5000).  These compositions in a 82/10/8 ratio of mole percentages, respectively, is also preferred.  The DPPC component is effectively neutral, since the phosphtidyl portion is
negatively charged and the choline portion is positively charged.  Consequently, the DPPA component, which is negatively charged, is added to enhance stabilization in accordance with the mechanism described further above regarding negatively charged
lipids as an additional agent.  The third component, DPPE/PEG, provides a PEGylated material bound to the lipid membrane or skin of the microsphere by the DPPE moiety, with the PEG moiety free to surround the microsphere membrane or skin, and thereby
form a physical barrier to various enzymatic and other endogenous agents in the body whose function is to degrade such foreign materials.  It is also theorized that the PEGylated material, because of its structural similarity to water, is able to defeat
the action of the macrophages of the human immune system, which would otherwise tend to surround and remove the foreign object.  The result is an increase in the time during which the stabilized microspheres can function as MRI contrast media.


Other and Auxiliary Stabilizing Compounds


It is also contemplated to be a part of the present invention to prepare stabilized gas and gaseous precursor filled microspheres using compositions of matter in addition to the biocompatible lipids and polymers described above, provided that the
microspheres so prepared meet the stability and other criteria set forth herein.  These compositions may be basic and fundamental, i.e., form the primary basis for creating or establishing the stabilized gas and gaseous precursor filled microspheres.  On
the other hand, they may be auxiliary, i.e., act as subsidiary or supplementary agents which either enhance the functioning of the basic stabilizing compound or compounds, or else contribute some desired property in addition to that afforded by the basic
stabilizing compound.


However, it is not always possible to determine whether a given compound is a basic or an auxiliary agent, since the functioning of the compound in question is determined empirically, i.e., by the results produced with respect to producing
stabilized microspheres.  As examples of how these basic and auxiliary compounds may function, it has been observed that the simple combination of a biocompatible lipid and water or saline when shaken will often give a cloudy solution subsequent to
autoclaving for sterilization.  Such a cloudy solution may function a contrast agent, but is aesthetically objectionable and may imply instability in the form of undissolved or undispersed lipid particles.  Thus, propylene glycol may be added to remove
this cloudiness by facilitating dispersion or dissolution of the lipid particles.  The propylene glycol may also function as a thickening agent which improves microsphere formation and stabilization by increasing the surface tension on the microsphere
membrane or skin.  It is possible that the propylene glycol further functions as an additional layer that coats the membrane or skin of the microsphere, thus providing additional stabilization.  As examples of such further basic or auxiliary stabilizing
compounds, there are conventional surfactants which may be used; see D'Arrigo U.S.  Pat.  Nos.  4,684,479 and 5,215,680.


Additional auxiliary and basic stabilizing compounds include such agents as peanut oil, canola oil, olive oil, safflower oil, corn oil, or any other oil commonly known to be ingestible which is suitable for use as a stabilizing compound in
accordance with the requirements and instructions set forth in the instant specification.


In addition, compounds used to make mixed micelle systems may be suitable for use as basic or auxiliary stabilizing compounds, and these include, but are not limited to: lauryltrimethylammonium bromide (dodecyl-), cetyltrimethylammonium bromide
(hexadecyl-), myristyltrimethylammonium bromide (tetradecyl-), alkyldimethylbenzylammonium chloride (alkyl=C.sub.12,C.sub.14,C.sub.16,), benzyldimethyldodecylammonium bromide/chloride, benzyldimethyl hexadecylammonium bromide/chloride, benzyldimethyl
tetradecylammonium bromide/chloride, cetyldimethylethylammonium bromide/chloride, or cetylpyridinium bromide/chloride.


It has been found that the gas and gaseous precursor filled microspheres used in the present invention may be controlled according to size, solubility and heat stability by choosing from among the various additional or auxiliary stabilizing
agents described herein.  These agents can affect these parameters of the microspheres not only by their physical interaction with the lipid coatings, but also by their ability to modify the viscosity and surface tension of the surface of the gas and
gaseous precursor filled microsphere.  Accordingly, the gas and gaseous precursor filled microspheres used in the present invention may be favorably modified and further stabilized, for example, by the addition of one or more of a wide variety of (a)
viscosity modifiers, including, but not limited to carbohydrates and their phosphorylated and sulfonated derivatives; and polyethers, preferably with molecular weight ranges between 400 and 100,000; di- and trihydroxy alkanes and their polymers,
preferably with molecular weight ranges between 200 and 50,000; (b) emulsifying and/or solubilizing agents may also be used in conjunction with the lipids to achieve desired modifications and further stabilization; such agents include, but are not
limited to, acacia, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, mono-ethanolamine, oleic acid, oleyl alcohol, poloxamer (e.g., poloxamer 188, poloxamer 184, and poloxamer 181), polyoxyethylene
50 stearate, polyoxyl 35 castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol monostearate, sodium lauryl
sulfate, sodium stearate, sorbitan mono-laurate, sorbitan mono-oleate, sorbitan mono-palmitate, sorbitan monostearate, stearic acid, trolamine, and emulsifying wax; (c) suspending and/or viscosity-increasing agents that may be used with the lipids
include, but are not limited to, acacia, agar, alginic acid, aluminum mono-stearate, bentonite, magma, carbomer 934P, carboxymethylcellulose, calcium and sodium and sodium 12, carrageenan, cellulose, dextran, gelatin, guar gum, locust bean gum, veegum,
hydroxyethyl cellulose, hydroxypropyl methylcellulose, magnesium-aluminum-silicate, methylcellulose, pectin, polyethylene oxide, povidone, propylene glycol alginate, silicon dioxide, sodium alginate, tragacanth, xanthum gum, .alpha.-d-gluconolactone,
glycerol and mannitol; (d) synthetic suspending agents may also be utilized such as polyethyleneglycol (PEG), polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA), polypropylene glycol, and polysorbate; and (e) tonicity raising agents may be included; such
agents include but are not limited to sorbitol, propyleneglycol and glycerol.


Aqueous Diluents


As mentioned earlier, where the microspheres are lipid in nature, a particularly desired component of the stabilized microspheres is an aqueous environment of some kind, which induces the lipid, because of its hydrophobic/hydrophilic nature, to
form microspheres, the most stable configuration which it can achieve in such an environment.  The diluents which can be employed to create such an aqueous environment include, but are not limited to water, either deionized or containing any number of
dissolved salts, etc., which will not interfere with creation and maintenance of the stabilized microspheres or their use as MRI contrast agents; and normal saline and physiological saline.


Paramagnetic and Superparamagnetic Contrast Agents


In a further embodiment of the present invention, the stabilized gas filled microsphere based contrast medium of the invention may further comprise additional contrast agents such as conventional contrast agents, which may serve to increase the
efficacy of the contrast medium for MRI.  Many such contrast agents are well known to those skilled in the art and include paramagnetic and superparamagnetic contrast agents.


Exemplary paramagnetic contrast agents suitable for use in the subject invention include stable free radicals (such as, for example, stable nitroxides), as well as compounds comprising transition, lanthanide and actinide elements, which may, if
desired, be in the form of a salt or may be covalently or noncovalently bound to complexing agents (including lipophilic derivatives thereof) or to proteinaceous macromolecules.


Preferable transition, lanthanide and actinide elements include Gd(III), Mn(II), Cu(II), Cr(III), Fe(II), Fe(III), Co(II), Er(II), Ni(II), Eu(III) and Dy(III).  More preferably, the elements include Gd(III), Mn(II), Cu(II), Fe(II), Fe(III),
Eu(III) and Dy(III), especially Mn(II) and Gd(III).


These elements may, if desired, be in the form of a salt, such as a manganese salt, e.g., manganese chloride, manganese carbonate, manganese acetate, and organic salts of manganese such as manganese gluconate and manganese hydroxylapatite; and
such as an iron salt, e.g., iron sulfides and ferric salts such as ferric chloride.


These elements may also, if desired, be bound, e.g., covalently or noncovalently, to complexing agents (including lipophilic derivatives thereof) or to proteinaceous macromolecules.  Preferable complexing agents include, for example,
diethylenetriamine-pentaacetic acid (DTPA), ethylene-diaminetetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-N,N',N',N"'-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-N,N',N"-triacetic acid (DO3A),
3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyl-trideca noic acid (B-19036), hydroxybenzylethylene-diamine diacetic acid (HBED), N,N'-bis(pyridoxyl-5-phosphate)ethylene diamine, N,N'-diacetate (DPDP),
1,4,7-triazacyclononane-N,N',N"-triacetic acid (NOTA), 1,4,8,11-tetraazacyclotetradecane-N,N'N",N"'-tetraacetic acid (TETA), kryptands (that is, macrocyclic complexes), and desferrioxamine.  More preferably, the complexing agents are EDTA, DTPA, DOTA,
DO3A and kryptands, most preferably DTPA.  Preferable lipophilic complexes thereof include alkylated derivatives of the complexing agents EDTA, DOTA, etc., for example, EDTA-DDP, that is,
N,N'-bis-(carboxy-decylamidomethyl-N-2,3-dihydroxypropyl)ethylenediamine-N ,N'-diacetate; EDTA-ODP, that is N,N'-bis(carboxy-octadecylamido-methyl-N-2,3-dihydroxypropyl)ethylenediami ne-N,N'-diacetate; EDTA-LDP
N,N'-Bis-(carboxylaurylamidomethyl-N-2,3-dihydroxypropyl)-ethylenediamine- N,N'-diacetate; etc.; such as those described in U.S.  Ser.  No. 887,290, filed May 22, 1992, the disclosures of which are hereby incorporated herein by reference in its entirety. Preferable proteinaceous macromolecules include albumin, collagen, polyarginine, polylysine, polyhistidine, .gamma.-globulin and .beta.-globulin.  More preferably, the proteinaceous macromolecules comprise albumin, polyarginine, polylysine, and
polyhistidine.


Suitable complexes thus include Mn(II)-DTPA, Mn(II)-EDTA, Mn(II)-DOTA, Mn(II)-DO3A, Mn(II)-kryptands, Gd(III)-DTPA, Gd(III)-DOTA, Gd(III)-DO3A, Gd(III)-kryptands, Cr(III)-EDTA, Cu(II)-EDTA, or iron-desferrioxamine, especially Mn(II)-DTPA or
Gd(III)-DTPA.


Nitroxides are paramagnetic contrast agents which increase both T1 and T2 relaxation rates by virtue of one unpaired electron in the nitroxide molecule.  The paramagnetic effectiveness of a given compound as an MRI contrast agent is at least
partly related to the number of unpaired electrons in the paragmagnetic nucleus or molecule, specifically to the square of the number of unpaired electrons.  For example, gadolinium has seven unpaired electrons and a nitroxide molecule has only one
unpaired electron; thus gadolinium is generally a much stronger MRI contrast agent than a nitroxide.  However, effective correlation time, another important parameter for assessing the effectiveness of contrast agents, confers potential increased
relaxivity to the nitroxides.  When the effective correlation time is very close to the proton Larmour frequency, the relaxation rate may increase dramatically.  When the tumbling rate is slowed, e.g., by attaching the paramagnetic contrast agent to a
large structure, it will tumble more slowly and thereby more effectively transfer energy to hasten relaxation of the water protons.  In gadolinium, however, the electron spin relaxation time is rapid and will limit the extent to which slow rotational
correlation times can increase relaxivity.  For nitroxides, however, the electron spin correlation times are more favorable and tremendous increases in relaxivity may be attained by slowing the rotational correlation time of these molecules.  The gas
filled microspheres of the present invention are ideal for attaining the goals of slowed rotational correlation times and resultant improvement in relaxivity.  Although not intending to be bound by any particular theory of operation, it is contemplated
that since the nitroxides may be designed to coat the perimeters of the gas filled microspheres, e.g., by making alkyl derivatives thereof, that the resulting correlation times can be optimized.  Moreover, the resulting contrast medium of the present
invention may be viewed as a magnetic sphere, a geometric configuration which maximizes relaxivity.


If desired, the nitroxides may be alkylated or otherwise derivitized, such as the nitroxides 2,2,5,5-tetramethyl-1-pyrrolidinyloxy, free radical, and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TMPO),


Exemplary superparamagnetic contrast agents suitable for use in the subject invention include metal oxides and sulfides which experience a magnetic domain, ferro- or ferrimagnetic compounds, such as pure iron, magnetic iron oxide (such as
magnetite), .gamma.-Fe.sub.2 O.sub.3, manganese ferrite, cobalt ferrite and nickel ferrite.


The contrast agents, such as the paramagnetic and superparamagnetic contrast agents described above, may be employed as a component within the microspheres or in the contrast medium comprising the microspheres.  They may be entrapped within the
internal space of the microspheres, administered as a solution with the microspheres or incorporated into the stabilizing compound forming the microsphere wall.


For example, if desired, the paramagnetic or superparamagnetic agents may be delivered as alkylated or other derivatives incorporated into the stabilizing compound, especially the lipidic walls of the microspheres.  In particular, the nitroxides
2,2,5,5-tetramethyl-1-pyrrolidinyloxy, free radical and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical, can form adducts with long chain fatty acids at the positions of the ring which are not occupied by the methyl groups, via a number of different
linkages, e.g., an acetyloxy group.  Such adducts are very amenable to incorporation into the stabilizing compounds, especially those of a lipidic nature, which form the walls of the microspheres of the present invention.


Mixtures of any one or more of the paramagnetic agents and/or superparamagnetic agents in the contrast media may similarly be used.


The paramagnetic and superparamagnetic agents described above may also be coadministered separately, if desired.


The gas filled microspheres used in the present invention may not only serve as effective carriers of the superparamagnetic agents, e.g., iron oxides, but also appear to magnify the effect of the susceptibility contrast agents.  Superparamagnetic
contrast agents include metal oxides, particularly iron oxides but including manganese oxides, and as iron oxides, containing varying amounts of manganese, cobalt and nickel which experience a magnetic domain.  These agents are nano or microparticles and
have very high bulk susceptibilities and transverse relaxation rates.  The larger particles, e.g., 100 nm diameter, have much higher R2 relaxivities than R1 relaxivities but the smaller particles, e.g., 10 to 15 nm diameter have somewhat lower R2
relaxivities, but much more balanced R1 nd R2 values.  The smallest particles, e.g., monocrystalline iron oxide particles, 3 to 5 nm in diameter, have lower R2 relaxivities, but probably the most balanced R1 and R2 relaxation rates.  Ferritin can also be
formulated to encapsulate a core of very high relaxation rate superparamagnetic iron.  It has been discovered that stabilized gas filled microspheres used in the present invention can increase the efficacy and safety of these conventional iron oxide
based MRI contrast agents.


The iron oxides may simply be incorporated into the stabilizing compounds from which the microspheres are made.  Particularly, the iron oxides may be incorporated into the walls of the lipid based microspheres, e.g., adsorbed onto the surfaces of
the microspheres, or entrapped within the interior of the microspheres as described in U.S.  Pat.  No. 5,088,499, issued Feb.  18, 1992.  Although there is no intention to limit the present invention to any particular theory as to its mode of action, it
is believed that the microspheres increase the efficacy of the superparamagnetic contrast agents by several mechanisms.  First, it is believed that the microspheres function so as to increase the apparent magnetic concentration of the iron oxide
particles.  Second, it is believed that the microspheres increase the apparent rotational correlation time of the MRI contrast agents, both paramagnetic and superparamagnetic agents, so that relaxation rates are increased.  Finally, the microspheres
appear to operate by way of a novel mechanism which increases the apparent magnetic domain of the contrast medium and is believed to operate in the manner described immediately below.


The microspheres may be thought of as flexible spherical domains of differing susceptibility from the suspending medium, i.e., the aqueous suspension of the contrast medium and the gastrointestinal fluids in the case of gastrointestinal
administration, and blood or other body fluids in the cases of intravascular injection or injection into another body space.  When considering ferrites or iron oxide particles, it should be noted that these agents have a particle size dependent effect on
contrast, i.e., it depends on the particle diameter of the iron oxide particle.  This phenomenon is very common and is often referred to as the "secular" relaxation of the water molecules.  Described in more physical terms, this relaxation mechanism is
dependent upon the effective size of the molecular complex in which a paramagnetic atom, or paramagnetic molecule, or molecules, may reside.  One physical explanation may be described in the following Solomon-Bloembergen equations which define the
paramagnetic contributions to the T.sub.1 and T.sub.2 relaxation times of a spin 1/2 nucleus with gyromagnetic ratio g perturbed by a paramagnetic ion:


and


where:


S=electron spin quantum number;


g=electronic g factor;


.beta.=Bohr magneton;


.omega..sub.l and .omega..sub.s (=657 w.sub.l)=Larmor angular precession frequencies for the nuclear spins and electron spins;


r=ion-nucleus distance;


A=hyperfine coupling constant;


T.sub.c and T.sub.e =correlation times for the dipolar and scalar interactions, respectively; and


h=Planck's constant


See, e.g., Solomon, I. Phys. Rev.  99, 559 (1955) and Bloembergen, N. J. Chem. Phys. 27, 572, 595 (1957)


A few large particles will generally have a much greater effect than a larger number of much smaller particles, primarily due to a larger correlation time.  If one were to make the iron oxide particles very large however, they might be toxic and
embolize the lungs or activate the complement cascade system.  Furthermore, it is not the total size of the particle that matters, but particularly the diameter of the particle at its edge or outer surface.  The domain of magnetization or susceptibility
effect falls off exponentially from the surface of the particle.  Generally speaking, in the case of dipolar (through space) relaxation mechanisms, this exponential fall off exhibits an r.sup.6 dependence.  Literally interpreted, a water molecule that is
4 angstroms away from a paramagnetic surface will be influenced 64 times less than a water molecule that is 2 angstroms away from the same paramagnetic surface.  The ideal situation in terms of maximizing the contrast effect would be to make the iron
oxide particles hollow, flexible and as large as possible.  Up until now it has not been possible to do this; furthermore, these benefits have probably been unrecognized until now.  By coating the inner or outer surfaces of the microspheres with the
contrast agents, even though the individual contrast agents, e.g., iron oxide nanoparticles or paramagnetic ions, are relatively small structures, the effectiveness of the contrast agents may be greatly enhanced.  In so doing, the contrast agents may
function as an effectively much larger sphere wherein the effective domain of magnetization is determined by the diameter of the microsphere and is maximal at the surface of the microsphere.  These agents afford the advantage of flexibility, i.e.,
compliance.  While rigid microspheres might lodge in the lungs or other organs and cause toxic reactions, these flexible microspheres slide through the capillaries much more easily.


Furthermore, the microsphere based contrast media of the present invention can be used to measure pressures non-invasively by NMR in vivo.  As noted above, the magnetic domain depends upon the diameter of the microspheres.  As the microspheres
encounter regions of higher pressure in vivo, due to their flexibility, they decrease in diameter and relaxivity then decreases.  By measuring 1/T2* (the effect on the non-refocused relaxation rate) or signal intensity one can then infer the effects on
pressure non-invasivley in vivo.


Specifically, as shown in the accompanying figures, these magnetically active microspheres may be used for estimating pressure by magnetic resonance imaging.  The microspheres increase the bulk susceptibility and accordingly increase T.sub.2
relaxation but even more so for T.sub.2 * relaxation.  Because the effects of static field gradients are mainly compensated in spin echo experiments (by virtue of the 180.degree.  Radiofrequency refocusing pulse) the effect of the bubbles is less marked
on T.sub.2 than T.sub.2 * weighted pulse sequences where static field effects are not compensated.  Increasing pressure results in loss of microsphere or microsphere disruption (for more soluble gases) as well as a decrease in microsphere diameter. 
Accordingly 1/T.sub.2 decreases with increasing pressure.  After release of pressure some of the remaining microspheres reexpand and 1/T.sub.2 increases again slightly.  Microspheres composed of about 80% PFP with 20% air show enhanced stability and a
slight fall in 1/T.sub.2 with pressure which returns to baseline after release of pressure (i.e., the micropheres are stable but show a slight 1/T.sub.2 pressure).  When gradient echo images are obtained and signal intensity measured these effects are
much more marked.  Signal intensity increases with increasing pressure (1/T.sub.2 * decreases with increased pressure).  Because the experiment is performed relatively quickly (it takes less than a tenth the time to perform the gradient echo images than
to measure T.sub.2).  The duration of exposure to pressure is much less and the nitrogen microspheres return nearly to baseline after pressure release (i.e. there is very little loss of microspheres).  Accordingly the signal intensity on gradient echo
falls back nearly to baseline at return to ambient pressure.  Thus, for measurement of pressure by MRI or ultrasound the bubbles can either be designed to fall apart with increasing pressure or to be stable but decrease bubble diameter with increasing
pressure.  Because an MRI bubble radius affects 1/T.sub.2 *, this relationship can be used to estimate pressure by MRI.


Thus the present invention further provides a method for determining the pressure in localized tissue of a patient comprising administering to the localized tissue gas filled microspheres, scanning said localized tissue using magnetic resonance
imaging to ascertain 1/T2, 1/T2* or signal intensity values, and comparing said 1/T2, 1/T2* or signal intensity values to other known 1/T2, 1/T2* or signal intensity values to estimate the pressure in said localized tissue.  The known 1/T2, 1/T2*, or
signal intensity values may be a preadministration (prior to administration to the patient) 1/T2, 1/T2*, or signal intensity value taken at a known pressure, temperature and/or microsphere radius, or may be a 1/T2, 1/T2* or signal intensity value taken
at another localized tissue of a patient Thus, after a comparison of the 1/T2, 1/T2* or signal intensity values, a pressure estimate may be made of the absolute pressure in the localized tissue of interest, or of a change in pressure between the
localized tissue of interest and another localized tissue.


Similarly, as one skilled in the art would recognize, once armed with the present disclosure, the foregoing process for measuring pressure may also be advantageously employed in determining the temperature in localized tissue of a patient.  Thus,
the present invention additionally provides a method for determining the temperature in localized tissue of a patient comprising administering to the localized tissue gas filled microspheres, scanning said localized tissue using magnetic resonance
imaging to ascertain 1/T2, 1/T2* or signal intensity values, and comparing said 1/T2, 1/T2* or signal intensity values to other known 1/T2, 1/T2* or signal intensity values to estimate the temperature in said localized tissue.


Methods of Preparation


The stabilized gas filled microspheres used in the present invention may be prepared by a number of suitable methods.  These are described below separately for the case where the microspheres are gas filled, and where they are gaseous precursor
filled, although microspheres having both a gas and gaseous precursor are part of the present invention.


-Utilizing a Gas


A preferred embodiment comprises the steps of agitating an aqueous solution comprising a stabilizing compound, preferably a lipid, in the presence of a gas at a temperature below the gel to liquid crystalline phase transition temperature of the
lipid to form gas filled microspheres.  The term agitating, and variations thereof, as used herein, means any motion that shakes an aqueous solution such that gas is introduced from the local ambient environment into the aqueous solution.  The shaking
must be of sufficient force to result in the formation of microspheres, particularily stabilized microspheres.  The shaking may be by swirling, such as by vortexing, side-to-side, or up-and-down motion.  Different types of motion may be combined.  Also,
the shaking may occur by shaking the container holding the aqueous lipid solution, or by shaking the aqueous solution within the container without shaking the container itself.


Further, the shaking may occur manually or by machine.  Mechanical shakers that may be used include, for example, a shaker table such as a VWR Scientific (Cerritos, Calif.) shaker table, or a Wig-L-Bug.RTM.  Shaker from Crescent Dental Mfg. Ltd.,
Lyons, Ill., which has been found to give excellent results.  It is a preferred embodiment of the present invention that certain modes of shaking or vortexing be used to make stable microspheres within a preferred size range.  Shaking is preferred, and
it is preferred that this shaking be carried out using the Wig-L-Bug.RTM.  mechanical shaker.  In accordance with this preferred method, it is preferred that a reciprocating motion be utilized to generate the gas filled microspheres.  It is even more
preferred that the motion be reciprocating in the form of an arc.  It is still more preferred that the motion be reciprocating in the form of an arc between about 2.degree.  and about 20.degree., and yet further preferred that the arc be between about
5.degree.  and about 8.degree..  It is most preferred that the motion is reciprocating between about 6.degree.  and about 7.degree., most particularly about 6.5.degree..  It is contemplated that the rate of reciprocation, as well as the arc thereof, is
critical to determining the amount and size of the gas filled microspheres formed.  It is a preferred embodiment of the present invention that the number of reciprocations, i.e., full cycle oscillations, be within the range of about 1000 and about 20,000
per minute.  More preferably, the number of reciprocations or oscillations will be between 2500 and 8000.  The Wig-L-Bug.RTM., referred to above, is a mechanical shaker which provides 2000 pestle strikes every 10 seconds, i.e., 6000 oscillations every
minute.  Of course, the number of oscillations is dependent upon the mass of the contents being agitated, with the larger the mass, the fewer the number of oscillations).  Another means for producing shaking includes the action of gas emitted under high
velocity or pressure.


It will also be understood that preferably, with a larger volume of aqueous solution, the total amount of force will be correspondingly increased.  Vigorous shaking is defined as at least about 60 shaking motions per minute, and is preferred. 
Vortexing at least 60-300 revolutions per minute is more preferred.  Vortexing at 300-1800 revolutions per minute is most preferred.  The formation of gas filled microspheres upon shaking can be detected visually.  The concentration of lipid required to
form a desired stabilized microsphere level will vary depending upon the type of lipid used, and may be readily determined by routine experimentation.  For example, in preferred embodiments, the concentration of 1,2-dipalimitoyl-phosphatidylcholine
(DPPC) used to form stabilized microspheres according to the methods of the present invention is about 0.1 mg/ml to about 30 mg/ml of saline solution, more preferably from about 0.5 mg/ml to about 20 mg/ml of saline solution, and most preferably from
about 1 mg/ml to about 10 mg/ml of saline solution.  The concentration of distearoylphosphatidylcholine (DSPC) used in preferred embodiments is about 0.1 mg/ml to about 30 mg/ml of saline solution, more preferably from about 0.5 mg/ml to about 20 mg/ml
of saline solution, and most preferably from about 1 mg/ml to about 10 mg/ml of saline solution.


In addition to the simple shaking methods described above, more elaborate, but for that reason less preferred, methods can also be employed, e.g., liquid crystalline shaking gas instillation processes, and vacuum drying gas instillation
processes, such as those described in U.S.  Ser.  No. 076,250, filed Jun.  11, 1993, which is incorporated herein by reference, in its entirety.  When such processes are used, the stabilized microspheres which are to be gas filled, may be prepared prior
to gas installation using any one of a variety of conventional liposome preparatory techniques which will be apparent to those skilled in the art.  These techniques include freeze-thaw, as well as techniques such as sonication, chelate dialysis,
homogenization, solvent infusion, microemulsification, spontaneous formation, solvent vaporization, French pressure cell technique, controlled detergent dialysis, and others, each involving preparing the microspheres in various fashions in a solution
containing the desired active ingredient so that the therapeutic, cosmetic or other agent is encapsulated in, enmeshed in, or attached the resultant polar-lipid based microsphere.  See, e.g., Madden et al, Chemistry and Physics of Lipids, 1990 53, 37-46,
the disclosure of which is hereby incorporated herein by reference in its entirety.


The gas filled microspheres prepared in accordance with the methods described above range in size from below a micron to over 100.mu.  in size.  In addition, it will be noted that after the extrusion and sterilization procedures, the agitation or
shaking step yields gas filled microspheres with little to no residual anhydrous lipid phase (Bangham, A. D., Standish, M. M, & Watkins, J. C. (1965) J. Mol. Biol.  13, 238-252) present in the remainder of the solution.  The resulting gas filled
microspheres remain stable on storage at room temperature for a year or even longer.


The size of gas filled microspheres can be adjusted, if desired, by a variety of procedures including microemulsification, vortexing, extrusion, filtration, sonication, homogenization, repeated freezing and thawing cycles, extrusion under
pressure through pores of defined size, and similar methods.  It may also be desirable to use the microspheres of the present invention as they are formed, without any attempt at further modification of the size thereof.


The gas filled microspheres may be sized by a simple process of extrusion through filters; the filter pore sizes control the size distribution of the resulting gas filled microspheres.  By using two or more cascaded, i.e., a stacked set of
filters, e.g., 10.mu.  followed by 8.mu., the gas filled microspheres have a very narrow size distribution centered around 7-9 .mu.m.  After filtration, these stabilized gas filled microspheres remain stable for over 24 hours.


The sizing or filtration step may be accomplished by the use of a filter assembly when the suspension is removed from a sterile vial prior to use, or even more preferably, the filter assembly may be incorporated into the syringe itself during
use.  The method of sizing the microspheres will then comprise using a syringe comprising a barrel, at least one filter, and a needle; and will be carried out by a step of extracting which comprises extruding said microspheres from said barrel through
said filter fitted to said syringe between said barrel and said needle, thereby sizing said microspheres before they are administered to a patient in the course of using the microspheres as MRI contrast agents in accordance with the present invention. 
The step of extracting may also comprise drawing said microspheres into said syringe, where the filter will function in the same way to size the microspheres upon entrance into the syringe.  Another alternative is to fill such a syringe with microspheres
which have already been sized by some other means, in which case the filter now functions to ensure that only microspheres within the desired size range, or of the desired maximum size, are subsequently administered by extrusion from the syringe.


Typical of the devices which can be used for carrying out the sizing or filtration step, is the syringe and filter combination shown in FIG. 2.  This device consists of a cascade filter housing 10, which may be fitted directly onto a syringe 12,
comprising a barrel 4 and a plunger 6, thereby allowing cascade filtration at the point of use.


FIG. 3 shows further detail regarding the filter.  The filter housing 10 comprises a cascade filter assembly 24, incorporated between a lower collar 22, having male threads, and a female collar 14, having female threads.  The lower collar 22 is
fitted with a Luer lock that allows it to be readily secured to the syringe 12 and the upper collar 14 is fitted with a needle 26.  An exploded view of the cascade filter assembly 24, is also shown in FIG. 3.  It comprises two successive filters 16 and
20, with filter 20 being disposed upstream of filter 16.  In a preferred embodiment, the upstream filter 20 is a "NUCLEPORE" 10 .mu.m filter and the downstream filter 16 is a "NUCLEPORE" 8 .mu.m filter.  Two 0.15 mm metallic mesh discs 15 are preferably
installed on either side of the filter 16.  In a preferred embodiment, the filters 16 and 20 are spaced apart a minimum of 150 .mu.m by means of a Teflon.TM.  O-ring, 18.


In preferred embodiments, the stabilizing compound solution or suspension is extruded through a filter and the said solution or suspension is heat sterilized prior to shaking.  Once gas filled microspheres are formed, they may be filtered for
sizing as described above.  These steps prior to the formation of gas filled microspheres provide the advantages, for example, of reducing the amount of unhydrated stabilizing compound, and thus providing a significantly higher yield of gas filled
microspheres, as well as and providing sterile gas filled microspheres ready for administration to a patient.  For example, a mixing vessel such as a vial or syringe may be filled with a filtered stabilizing compound, especially lipid suspension, and the
suspension may then be sterilized within the mixing vessel, for example, by autoclaving.  Gas may be instilled into the lipid suspension to form gas filled microspheres by shaking the sterile vessel.  Preferably, the sterile vessel is equipped with a
filter positioned such that the gas filled microspheres pass through the filter before contacting a patient.


The first step of this preferred method, extruding the stabilizing, especially lipid, solution through a filter, decreases the amount of unhydrated compound by breaking up the dried compound and exposing a greater surface area for hydration. 
Preferably, the filter has a pore size of about 0.1 to about 5 .mu.m, more preferably, about 0.1 to about 4 .mu.m, even more preferably, about 0.1 to about 2 .mu.m, and most preferably, about 1 .mu.m.  Unhydrated compound, especially lipid, appears as
amorphous clumps of non-uniform size and is undesirable.


The second step, sterilization, provides a composition that may be readily administered to a patient for MRI imaging.  Preferably, sterilization is accomplished by heat sterilization, preferably, by autoclaving the solution at a temperature of at
least about 100.degree.  C., and more preferably, by autoclaving at about 100.degree.  C. to about 130.degree.  C., even more preferably, about 110.degree.  C. to about 130.degree.  C., even more preferably, about 120.degree.  C. to about 130.degree. 
C., and most preferably, about 130.degree.  C. Preferably, heating occurs for at least about 1 minute, more preferably, about 1 to about 30 minutes, even more preferably, about 10 to about 20 minutes, and most preferably, about 15 minutes.


If desired, alternatively the first and second steps, as outlined above, may be reversed, or only one of the two steps employed.


Where sterilization occurs by a process other than heat sterilization at a temperature which would cause rupture of the gas filled microspheres, sterilization may occur subsequent to the formation of the gas filled microspheres, and is preferred. For example, gamma radiation may be used before and/or after gas filled microspheres are formed.


-Utilizing a Gaseous Precursor


In addition to the aforementioned embodiments, one can also use gaseous precursors contained in the lipid-based microspheres that can, upon activation by temperature, light, or pH, or other properties of the tissues of a host to which it is
administered, undergo a phase transition from a liquid entrapped in the lipid-based microspheres, to a gaseous state, expanding to create the stabilized, gas filled microspheres used in the present invention.  This technique is described in detail in
patent application Ser.  Nos.  08/160,232, filed Nov.  30, 1993, and 08/159,687, filed Nov.  30, 1993, both of which are incorporated herein by reference in their entirety.  The techniques for preparing gaseous precursor filled microspheres are generally
similar to those described for the preparation of gas filled microspheres herein, except that a gaseous precursor is substituted for the gas.


The preferred method of activating the gaseous precursor is by temperature.  Activation or transition temperature, and like terms, refer to the boiling point of the gaseous precursor, the temperature at which the liquid to gaseous phase
transition of the gaseous precursor takes place.  Useful gaseous precursors are those gases which have boiling points in the range of about -100.degree.  C. to 70.degree.  C. The activation temperature is particular to each gaseous precursor.  An
activation temperature of about 37.degree.  C., or human body temperature, is preferred for gaseous precursors of the present invention.  Thus, a liquid gaseous precursor is activated to become a gas at 37.degree.  C. However, the gaseous precursor may
be in liquid or gaseous phase for use in the methods of the present invention.  The methods of preparing the MRI contrast agents used in the present invention may be carried out below the boiling point of the gaseous precursor such that a liquid is
incorporated into a microsphere.  In addition, the said methods may be performed at the boiling point of the gaseous precursor such that a gas is incorporated into a microsphere.  For gaseous precursors having low temperature boiling points, liquid
precursors may be emulsified using a microfluidizer device chilled to a low temperature.  The boiling points may also be depressed using solvents in liquid media to utilize a precursor in liquid form.  Further, the methods may be performed where the
temperature is increased throughout the process, whereby the process starts with a gaseous precursor as a liquid and ends with a gas.


The gaseous precursor may be selected so as to form the gas in situ in the targeted tissue or fluid, in vivo upon entering the patient or animal, prior to use, during storage, or during manufacture.  The methods of producing the
temperature-activated gaseous precursor-filled microspheres may be carried out at a temperature below the boiling point of the gaseous precursor.  In this embodiment, the gaseous precursor is entrapped within a microsphere such that the phase transition
does not occur during manufacture.  Instead, the gaseous precursor-filled microspheres are manufactured in the liquid phase of the gaseous precursor.  Activation of the phase transition may take place at any time as the temperature is allowed to exceed
the boiling point of the precursor.  Also, knowing the amount of liquid in a droplet of liquid gaseous precursor, the size of the microspheres upon attaining the gaseous state may be determined.


Alternatively, the gaseous precursors may be utilized to create stable gas filled microspheres which are pre-formed prior to use.  In this embodiment, the gaseous precursor is added to a container housing a suspending and/or stabilizing medium at
a temperature below the liquid-gaseous phase transition temperature of the respective gaseous precursor.  As the temperature is then exceeded, and an emulsion is formed between the gaseous precursor and liquid solution, the gaseous precursor undergoes
transition from the liquid to the gaseous state.  As a result of this heating and gas formation, the gas displaces the air in the head space above the liquid suspension so as to form gas filled lipid spheres which entrap the gas of the gaseous precursor,
ambient gas (e.g., air) or coentrap gas state gaseous precursor and ambient air.  This phase transition can be used for optimal mixing and stabilization of the MRI contrast medium.  For example, the gaseous precursor, perfluorobutane, can be entrapped in
the biocompatible lipid or other stabilizing compound, and as the temperature is raised, beyond 4.degree.  C. (boiling point of perfluorobutane) stabilizing compound entrapped fluorobutane gas results.  As an additional example, the gaseous precursor
fluorobutane, can be suspended in an aqueous suspension containing emulsifying and stabilizing agents such as glycerol or propylene glycol and vortexed on a commercial vortexer.  Vortexing is commenced at a temperature low enough that the gaseous
precursor is liquid and is continued as the temperature of the sample is raised past the phase transition temperature from the liquid to gaseous state.  In so doing, the precursor converts to the gaseous state during the microemulsification process.  In
the presence of the appropriate stabilizing agents, surprisingly stable gas filled microspheres result.


Accordingly, the gaseous precursors may be selected to form a gas filled microsphere in vivo or may be designed to produce the gas filled microsphere in situ, during the manufacturing process, on storage, or at some time prior to use.


As a further embodiment of this invention, by preforming the liquid state of the gaseous precursor into an aqueous emulsion and maintaining a known size, the maximum size of the microbubble may be estimated by using the ideal gas law, once the
transition to the gaseous state is effectuated.  For the purpose of making gas filled microspheres from gaseous precursors, the gas phase is assumed to form instantaneously and no gas in the newly formed microsphere has been depleted due to diffusion
into the liquid (generally aqueous in nature).  Hence, from a known liquid volume in the emulsion, one actually would be able to predict an upper limit to the size of the gaseous microsphere.


Pursuant to the present invention, an emulsion of a stabilizing compound such as a lipid, and a gaseous precursor, containing liquid droplets of defined size may be formulated, such that upon reaching a specific temperature, the boiling point of
the gaseous precursor, the droplets will expand into gas filled microspheres of defined size.  The defined size represents an upper limit to the actual size because factors such as gas diffusion into solution, loss of gas to the atmosphere, and the
effects of increased pressure are factors for which the ideal gas law cannot account.


The ideal gas law and the equation for calculating the increase in volume of the gas bubbles on transition from the liquid to gaseous states is as follows:


where


P=pressure in atmospheres


V=volume in liters


n=moles of gas


T=temperature in .degree.  K.


R=ideal gas constant=22.4 L atmospheres deg.sup.-1 mole.sup.-1


With knowledge of volume, density, and temperature of the liquid in the emulsion of liquids, the amount (e.g., number of moles) of liquid precursor as well as the volume of liquid precursor, a priori, may be calculated, which when converted to a
gas, will expand into a microsphere of known volume.  The calculated volume will reflect an upper limit to the size of the gas filled microsphere, assuming instantaneous expansion into a gas filled microsphere and negligible diffusion of the gas over the
time of the expansion.


Thus, for stabilization of the precursor in the liquid state in an emulsion wherein the precursor droplet is spherical, the volume of the precursor droplet may be determined by the equation:


where


r=radius of the sphere


Thus, once the volume is predicted, and knowing the density of the liquid at the desired temperature, the amount of liquid (gaseous precursor) in the droplet may be determined.  In more descriptive terms, the following can be applied:


by the ideal gas law,


substituting reveals,


or,


(A) n=4/3 [.pi.r.sub.gas.sup.3 ] P/RT


 amount n=4/3 [.pi.r.sub.gas.sup.3 P/RT]*MW.sub.n


Converting back to a liquid volume


(B) V.sub.liq =[4/3 [.pi.r.sub.gas.sup.3 ] P/RT]*MW.sub.n /D]


where D=the density of the precursor


Solving for the diameter of the liquid droplet,


(C) diameter/2=[3/4.pi.[4/3*[.pi.r.sub.gas.sup.3 ] P/RT] MW.sub.n /D].sup.1/3


which reduces to


Diameter=2[[r.sub.gas.sup.3 ] P/RT [MW.sub.n /D]].sup.1/3


As a further means of preparing microspheres of the desired size for use as MRI contrast agents in the present invention, and with a knowledge of the volume and especially the radius of the stabilizing compound/precursor liquid droplets, one can
use appropriately sized filters in order to size the gaseous precursor droplets to the appropriate diameter sphere.


A representative gaseous precursor may be used to form a microsphere of defined size, for example, 10.mu.  diameter.  In this example, the microsphere is formed in the bloodstream of a human being, thus the typical temperature would be 37.degree. C. or 310.degree.  K. At a pressure of 1 atmosphere and using the equation in (A), 7.54.times.10.sup.-17 moles of gaseous precursor would be required to fill the volume of a 10.mu.  diameter microsphere.


Using the above calculated amount of gaseous precursor, and 1-fluorobutane, which possesses a molecular weight of 76.11, a boiling point of 32.5.degree.  C. and a density of 0.7789 grams/mL.sup.-1 at 20.degree.  C., further calculations predict
that 5.74.times.10.sup.-15 grams of this precursor would be required for a 10.mu.  microsphere.  Extrapolating further, and armed with the knowledge of the density, equation (B) further predicts that 8.47.times.10.sup.-16 mLs of liquid precursor are
necessary to form a microsphere with an upper limit of 10.mu..


Finally, using equation (C), an emulsion of lipid droplets with a radius of 0.0272.mu.  or a corresponding diameter of 0.0544.mu.  need be formed to make a gaseous precursor filled microsphere with an upper limit of a 10.mu.  microsphere.


An emulsion of this particular size could be easily achieved by the use of an appropriately sized filter.  In addition, as seen by the size of the filter necessary to form gaseous precursor droplets of defined size, the size of the filter would
also suffice to remove any possible bacterial contaminants and, hence, can be used as a sterile filtration as well.


This embodiment for preparing gas filled microspheres used as MRI contrast agents in the methods of the present invention may be applied to all gaseous precursors activated by temperature.  In fact, depression of the freezing point of the solvent
system allows the use gaseous precursors which would undergo liquid-to-gas phase transitions at temperatures below 0.degree.  C. The solvent system can be selected to provide a medium for suspension of the gaseous precursor.  For example, 20% propylene
glycol miscible in buffered saline exhibits a freezing point depression well below the freezing point of water alone.  By increasing the amount of propylene glycol or adding materials such as sodium chloride, the freezing point can be depressed even
further.


The selection of appropriate solvent systems may be explained by physical methods as well.  When substances, solid or liquid, herein referred to as solutes, are dissolved in a solvent, such as water based buffers for example, the freezing point
is lowered by an amount that is dependent upon the composition of the solution.  Thus, as defined by Wall, one can express the freezing point depression of the solvent by the following equation:


where:


x.sub.a =mole fraction of the solvent


x.sub.b =mole fraction of the solute


.DELTA.H.sub.fus =heat of fusion of the solvent


T.sub.o =Normal freezing point of the solvent


The normal freezing point of the solvent results from solving the equation.  If x.sub.b is small relative to x.sub.a, then the above equation may be rewritten:


The above equation assumes the change in temperature .DELTA.T is small compared to T.sub.2.  The above equation can be simplified further assuming the concentration of the solute (in moles per thousand grams of solvent) can be expressed in terms
of the molality, m. Thus,


where:


Ma=Molecular weight of the solvent, and


m=molality of the solute in moles per 1000 grams.


Thus, substituting for the fraction x.sub.b :


K.sub.f is referred to as the molal freezing point and is equal to 1.86 degrees per unit of molal concentration for water at one atmosphere pressure.  The above equation may be used to accurately determine the molal freezing point of
gaseous-precursor filled microsphere solutions used in the present invention.


Hence, the above equation can be applied to estimate freezing point depressions and to determine the appropriate concentrations of liquid or solid solute necessary to depress the solvent freezing temperature to an appropriate value.


Methods of preparing the temperature activated gaseous precursor-filled microspheres include:


(a) vortexing an aqueous suspension of gaseous precursor-filled microspheres used in the present invention; variations on this method include optionally autoclaving before shaking, optionally heating an aqueous suspension of gaseous precursor and
lipid, optionally venting the vessel containing the suspension, optionally shaking or permitting the gaseous precursor microspheres to form spontaneously and cooling down the gaseous precursor filled microsphere suspension, and optionally extruding an
aqueous suspension of gaseous precursor and lipid through a filter of about 0.22.mu., alternatively, filtering may be performed during in vivo administration of the resulting microspheres such that a filter of about 0.22.mu.  is employed;


(b) a microemulsification method whereby an aqueous suspension of gaseous precursor-filled microspheres of the present invention are emulsified by agitation and heated to form microspheres prior to administration to a patient; and


(c) forming a gaseous precursor in lipid suspension by heating, and/or agitation, whereby the less dense gaseous precursor-filled microspheres float to the top of the solution by expanding and displacing other microspheres in the vessel and
venting the vessel to release air; and


(d) in any of the above methods, utilizing a sealed vessel to hold the aqueous suspension of gaseous precursor and stabilizing compound such as biocompatible lipid, said suspension being maintained at a temperature below the phase transition
temperature of the gaseous precursor, followed by autoclaving to move the temperature above the phase transition temperature, optionally with shaking, or permitting the gaseous precursor microspheres to form spontaneously, whereby the expanded gaseous
precursor in the sealed vessel increases the pressure in said vessel, and cooling down the gas filled microsphere suspension.


Freeze drying is useful to remove water and organic materials from the stabilizing compounds prior to the shaking gas instillation method.  Drying-gas instillation methods may be used to remove water from microspheres.  By pre-entrapping the
gaseous precursor in the dried microspheres (i.e., prior to drying) after warming, the gaseous precursor may expand to fill the microsphere.  Gaseous precursors can also be used to fill dried microspheres after they have been subjected to vacuum.  As the
dried microspheres are kept at a temperature below their gel state to liquid crystalline temperature, the drying chamber can be slowly filled with the gaseous precursor in its gaseous state, e.g., perfluorobutane can be used to fill dried microspheres
composed of dipalmitoylphosphatidylcholine (DPPC) at temperatures between 4.degree.  C. (the boiling point of perfluorobutane) and below 40.degree.  C., the phase transition temperature of the biocompatible lipid.  In this case, it would be most
preferred to fill the microspheres at a temperature about 4.degree.  C. to about 5.degree.  C.


Preferred methods for preparing the temperature activated gaseous precursor-filled microspheres comprise shaking an aqueous solution having a stabilizing compound such as a biocompatible lipid in the presence of a gaseous precursor at a
temperature below the gel state to liquid crystalline state phase transition temperature of the lipid.  The present invention also contemplates the use of a method for preparing gaseous precursor-filled microspheres comprising shaking an aqueous solution
comprising a stabilizing compound such as a biocompatible lipid in the presence of a gaseous precursor, and separating the resulting gaseous precursor-filled microspheres for MRI imaging use.  Microspheres prepared by the foregoing methods are referred
to herein as gaseous precursor-filled microspheres prepared by a gel state shaking gaseous precursor instillation method.


Conventional, aqueous-filled liposomes of the prior art are routinely formed at a temperature above the phase transition temperature of the lipids used to make them, since they are more flexible and thus useful in biological systems in the liquid
crystalline state.  See, for example, Szoka and Papahadjopoulos, Proc.  Natl.  Acad.  Sci.  1978, 75, 4194-4198.  In contrast, the microspheres made according to preferred embodiments described herein are gaseous precursor-filled, which imparts greater
flexibility, since gaseous precursors after gas formation are more compressible and compliant than an aqueous solution.  Thus, the gaseous precursor-filled microspheres may be utilized in biological systems when formed at a temperature below the phase
transition temperature of the lipid, even though the gel phase is more rigid.


The methods contemplated by the present invention provide for shaking an aqueous solution comprising a stabilizing compound such as a biocompatible lipid in the presence of a temperature activated gaseous precursor.  Shaking, as used herein, is
defined as a motion that agitates an aqueous solution such that gaseous precursor is introduced from the local ambient environment into the aqueous solution.  Any type of motion that agitates the aqueous solution and results in the introduction of
gaseous precursor may be used for the shaking.  The shaking must be of sufficient force to allow the formation of a suitable number of microspheres after a period of time.  Preferably, the shaking is of sufficient force such that microspheres are formed
within a short period of time, such as 30 minutes, and preferably within 20 minutes, and more preferably, within 10 minutes.  The shaking may be by microemulsifying, by microfluidizing, for example, swirling (such as by vortexing), side-to-side, or up
and down motion.  In the case of the addition of gaseous precursor in the liquid state, sonication may be used in addition to the shaking methods set forth above.  Further, different types of motion may be combined.  Also, the shaking may occur by
shaking the container holding the aqueous lipid solution, or by shaking the aqueous solution within the container without shaking the container itself.  Further, the shaking may occur manually or by machine.  Mechanical shakers that may be used include,
for example, a shaker table, such as a VWR Scientific (Cerritos, Calif.) shaker table, a microfluidizer, Wig-L-Bug.TM.  (Crescent Dental Manufacturing, Inc., Lyons, Ill.), which has been found to give particularly good results, and a mechanical paint
mixer, as well as other known machines.  Another means for producing shaking includes the action of gaseous precursor emitted under high velocity or pressure.  It will also be understood that preferably, with a larger volume of aqueous solution, the
total amount of force will be correspondingly increased.  Vigorous shaking is defined as at least about 60 shaking motions per minute, and is preferred.  Vortexing at least 1000 revolutions per minute, an example of vigorous shaking, is more preferred. 
Vortexing at 1800 revolutions per minute is most preferred.


The formation of gaseous precursor-filled microspheres upon shaking can be detected by the presence of a foam on the top of the aqueous solution.  This is coupled with a decrease in the volume of the aqueous solution upon the formation of foam. 
Preferably, the final volume of the foam is at least about two times the initial volume of the aqueous lipid solution; more preferably, the final volume of the foam is at least about three times the initial volume of the aqueous solution; even more
preferably, the final volume of the foam is at least about four times the initial volume of the aqueous solution; and most preferably, all of the aqueous lipid solution is converted to foam.


The required duration of shaking time may be determined by detection of the formation of foam.  For example, 10 ml of lipid solution in a 50 ml centrifuge tube may be vortexed for approximately 15-20 minutes or until the viscosity of the gaseous
precursor-filled microspheres becomes sufficiently thick so that it no longer clings to the side walls as it is swirled.  At this time, the foam may cause the solution containing the gaseous precursor-filled microspheres to raise to a level of 30 to 35
ml.


The concentration of stabilizing compound, especially lipid required to form a preferred foam level will vary depending upon the type of stabilizing compound such as biocompatible lipid used, and may be readily determined by one skilled in the
art, once armed with the present disclosure.  For example, in preferred embodiments, the concentration of 1,2-dipalimitoylphosphatidylcholine (DPPC) used to form gaseous precursor-filled microspheres according to methods contemplated by the present
invention is about 20 mg/ml to about 30 mg/ml saline solution.  The concentration of distearoylphosphatidylcholine (DSPC) used in preferred embodiments is about 5 mg/ml to about 10 mg/ml saline solution.


Specifically, DPPC in a concentration of 20 mg/ml to 30 mg/ml, upon shaking, yields a total suspension and entrapped gaseous precursor volume four times greater than the suspension volume alone.  DSPC in a concentration of 10 mg/ml, upon shaking,
yields a total volume completely devoid of any liquid suspension volume and contains entirely foam.


It will be understood by one skilled in the art, once armed with the present disclosure, that the lipids and other stabilizing compounds used as starting materials, or the microsphere final products, may be manipulated prior and subsequent to
being subjected to the methods contemplated by the present invention.  For example, the stabilizing compound such as a biocompatible lipid may be hydrated and then lyophilized, processed through freeze and thaw cycles, or simply hydrated.  In preferred
embodiments, the lipid is hydrated and then lyophilized, or hydrated, then processed through freeze and thaw cycles and then lyophilized, prior to the formation of gaseous precursor-filled microspheres.


According to the methods contemplated by the present invention, the presence of gas, such as and not limited to air, may also be provided by the local ambient atmosphere.  The local ambient atmosphere may be the atmosphere within a sealed
container, or in an unsealed container, may be the external environment.  Alternatively, for example, a gas may be injected into or otherwise added to the container having the aqueous lipid solution or into the aqueous lipid solution itself in order to
provide a gas other than air.  Gases that are not heavier than air may be added to a sealed container while gases heavier than air may be added to a sealed or an unsealed container.  Accordingly, the present invention includes co-entrapment of air and/or
other gases along with gaseous precursors.


As already described above in the section dealing with the stabilizing compound, the preferred methods contemplated by the present invention are carried out at a temperature below the gel state to liquid crystalline state phase transition
temperature of the lipid employed.  By "gel state to liquid crystalline state phase transition temperature", it is meant the temperature at which a lipid bilayer will convert from a gel state to a liquid crystalline state.  See, for example, Chapman et
al., J. Biol.  Chem. 1974, 249, 2512-2521.


Hence, the stabilized microsphere precursors described above, can be used in the same manner as the other stabilized microspheres used in the present invention, once activated by application to the tissues of a host, where such factors as
temperature or pH may be used to cause generation of the gas.  It is preferred that this embodiment is one wherein the gaseous precursors undergo phase transitions from liquid to gaseous states at near the normal body temperature of said host, and are
thereby activated by the temperature of said host tissues so as to undergo transition to the gaseous phase therein.  More preferably still, this method is one wherein the host tissue is human tissue having a normal temperature of about 37.degree.  C.,
and wherein the gaseous precursors undergo phase transitions from liquid to gaseous states near 37.degree.  C.


All of the above embodiments involving preparations of the stabilized gas filled microspheres used in the present invention, may be sterilized by autoclave or sterile filtration if these processes are performed before either the gas instillation
step or prior to temperature mediated gas conversion of the temperature sensitive gaseous precursors within the suspension.  Alternatively, one or more anti-bactericidal agents and/or preservatives may be included in the formulation of the contrast
medium, such as sodium benzoate, all quaternary ammonium salts, sodium azide, methyl paraben, propyl paraben, sorbic acid, ascorbylpalmitate, butylated hydroxyanisole, butylated hydroxytoluene, chlorobutanol, dehydroacetic acid, ethylenediamine,
monothioglycerol, potassium benzoate, potassium metabisulfite, potassium sorbate, sodium bisulfite, sulfur dioxide, and organic mercurial salts.  Such sterilization, which may also be achieved by other conventional means, such as by irradiation, will be
necessary where the stabilized micropheres are used for imaging under invasive circumstances, e.g., intravascularly or intraperitonealy.  The appropriate means of sterilization will be apparent to the artisan instructed by the present description of the
stabilized gas filled microspheres and their use.  The contrast medium is generally stored as an aqueous suspension but in the case of dried microspheres or dried lipidic spheres the contrast medium may be stored as a dried powder ready to be
reconstituted prior to use.


Methods of Use


The novel stabilized gas filled microspheres, useful as contrast media in magnetic resonance imaging (MRI), will be found to be suitable for use in all areas where MRI is employed.  However, the stabilized microspheres are particularly useful for
perfusion imaging and may also be utilized to obtain non-invasive pressure information in vivo.


In accordance with the present invention there is provided a method of imaging a patient generally, and/or in specifically diagnosing the presence of diseased tissue in a patient.  The imaging process of the present invention may be carried out
by administering a contrast medium of the invention to a patient, and then scanning the patient using magnetic resonance imaging to obtain visible images of an internal region of a patient and/or of any diseased tissue in that region.  By region of a
patient, it is meant the whole patient or a particular area or portion of the patient.  The contrast medium may be particularly useful in providing images of the cardiovascular region or the gastrointestinal region, but can also be employed more broadly
such as in imaging the vasculature or in other ways as will be readily apparent to those skilled in the art.  Cardiovacular region, as that phrase is used herein, denotes the region of the patient defined by the heart and the vasculature leading directly
to and from the heart.  The phrase gastrointestinal region or gastrointestinal tract, as used herein, includes the region of a patient defined by the esophagus, stomach, small and large intestines and rectum.  The phrase vasculature, as used herein,
denotes the blood vessels (arteries, veins, etc.) in the body or in an organ or part of the body.  The patient can be any type of mammal, but most preferably is a human.


As one skilled in the art would recognize, administration of the stabilized gas filled microspheres used in the present invention may be carried out in various fashions, such as intravascularly, orally, rectally, etc., using a variety of dosage
forms.  When the region to be scanned is the cardiovascular region, administration of the contrast medium of the invention is preferably carried out intravascularly.  When the region to be scanned is the gastrointestinal region, administration of the
contrast medium of the invention is preferably carried out orally or rectally.  The useful dosage to be administered and the particular mode of administration will vary depending upon the age, weight and the particular mammal and region thereof to be
scanned, and the particular contrast medium of the invention to be employed.  Typically, dosage is initiated at lower levels and increased until the desired contrast enhancement is achieved.  Various combinations of the stabilized gas filled microspheres
may be used to modify the relaxation behavior of the medium or to alter properties such as the viscosity, osmolarity or palatability (in the case of orally administered materials).  In carrying out the magnetic resonance imaging method of the present
invention, the contrast medium can be used alone, or in combination with other diagnostic, therapeutic or other agents.  Such other agents include excipients such as flavoring or coloring materials.  The magnetic resonance imaging techniques which are
employed are conventional and are described, for example, in D. M. Kean and M. A. Smith, Magnetic Resonance Imaging: Principles and Applications, (William and Wilkins, Baltimore 1986).  Contemplated MRI techniques include, but are not limited to, nuclear
magnetic resonance (NMR) and electronic spin resonance (ESR).  The preferred imaging modality is NMR.


As noted above, the routes of administration and areas of usefulness of the gas filled microspheres are not limited merely to the blood volume space, i.e., the vasculature.  MRI can be achieved with the gas filled microspheres used in the present
invention if the microspheres are ingested by mouth so as to image the gastrointestinal tract.  Alternatively, rectal administration of these stabilized gas microspheres can result in excellent imaging of the lower gastrointestinal tract including the
rectum, descending colon, transverse colon, and ascending colon as well as the appendix.  It may be possible to achieve imaging of the jejunum and conceivably the ileum via this rectal route.  As well, direct intraperitoneal administration may be
achieved to visualize the peritoneum.  It is also contemplated that the stabilized gas microspheres may be administered directly into the ear canals such that one can visualize the canals as well as the Eustachian tubes and, if a perforation exists, the
inner ear.  It is also contemplated that the stabilized gas microspheres may be administered intranasally to aid in the visualization of the nasal septum as well as the nasal sinuses by MRI.


Other routes of administration of the microsphere contrast agents of the present invention, and tissue areas whose imaging is enhanced thereby include, but are not limited to 1) intranasally for imaging the nasal passages and sinuses including
the nasal region and sinuses and sinusoids; 2) intranasally and orally for imaging the remainder of the respiratory tract, including the trachea, bronchus, bronchioles, and lungs; 3) intracochlearly for imaging the hearing passages and Eustachian tubes,
tympanic membranes and outer and inner ear and ear canals; 4) intraocularly for imaging the regions associated with vision; 5) intraperitoneally to visualize the peritoneum; and 6) intravesicularly, i.e., through the bladder, to image all regions of the
genitourinary tract via the areas thereof, including, but not limited to, the urethra, bladder, ureters, kidneys and renal vasculature and beyond, e.g., to perform cystography or to confirm the presence of ureteral reflux.


It has also been discovered that it is possible to use the gas filled microspheres used in the present invention to monitor the temperature of localized tissue by the use of gaseous precursor-filled stabilized microspheres in MRI.  As already
described, the magnetic domains of the spin=1/2 sensitive nuclei are altered at the interface between the gas and the surrounding aqueous-based media, e.g., blood.  It has been discovered that, as the gaseous precursors are moved through their
liquid-to-gas phase transition temperature, the magnetic domains are altered.  This can be visualized on MRI as a grey scale image, or by mapping the bulk susceptibility of the tissue.  With prior knowledge of the liquid-to-gas phase transition
temperature, one can then determine the extent of heating of localized tissue by the visualization of the bubbles by MRI.  Thus, the present invention includes a method for determining the temperature of localized tissue within the body of a human or
animal subject by means of stabilized gas filled microspheres, comprising the steps of (a) preparing a stabilized micropheres precursor by agitating an aqueous suspension of a lipid in the presence of one or more gaseous precursors which undergo phase
transitions from liquid to gaseous states in response to increased temperatures, optionally in the presence of a gas, whereby a said precursor comprising microspheres filled with liquid phase gaseous precursor is formed; (b) administering said stabilized
microspheres precursor prepared in the preceding step to the tissue of said subject; (c) activation of said gaseous precursor by increasing its temperature so that it undergoes transition to the gaseous phase, together with contemporaneous magnetic
resonance imaging of said tissue; and (d) observing that magnetic resonance image enhancement occurs at the phase transition temperature of the gaseous precursor, thereby determining the temperature of said localized tissue.  The increase in temperature
of said gaseous precursor can take place as a result of natural heating by said tissue to which it has been administered, or it can be the result of heating by the use of ultrasound, microwave energy, or other sources of energy applied to said localized
tissue.


Although MRI is currently capable of being used to measure vascular flow rates, to date there has been no suggestion of its use for measuring pressures within the bodies of humans or other mammals.  It is yet another aspect of the present
invention to accomplish such an objective by using the gas filled microspheres of the present invention and MRI technology.  It is contemplated that by using flexible gas filled microspheres as described herein, that it will be possible to non-invasively
measure pressures in vivo by MRI.  Since 1/T2.sup.* is proportional to the radius of the microspheres to the third power or even potentially the sixth power, and since the gas filled microspheres function as elastic bubbles, as they encounter higher
regions of pressure, the bubbles will compress and their radii will correspondingly decrease with increasing pressure.  And, as a result, 1/T2.sup.* will also decrease.  Thus, by using T2 or T2.sup.* weighted MR imaging pulse sequences and either
directly, or indirectly monitoring 1/T2.sup.* in different parts of the body, e.g., arteries and veins, it will be possible to obtain non-invasive measurements of pressure.


Accordingly, a method for determining the pressure of localized tissue within the body of a human or animal subject by means of stabilized gas filled microspheres, would comprise the steps of (a) preparing said stabilized micropheres by agitating
an aqueous suspension of a stabilizing compound in the presence of one or more gases and/or gaseous precursors, whereby said microspheres are formed; (b) administering said stabilized microspheres prepared in the preceding step to the tissue of said
subject; (c) magnetic resonance imaging said tissue and observing the 1/T2.sup.*, which is proportional to the radius of said microspheres, and the radii of said microspheres, which will correspondingly decrease with increasing pressure, also causing the
1/T2.sup.* to decrease; (d) monitoring 1/T2.sup.* in a different part of the body; and (e) by a comparison of the 1/T2.sup.* values and the proper calculation, determining the pressure of said localized tissue.


As already mentioned further above, FIGS. 1A and B shows a representative photomicrograph of stabilized gas filled microspheres used in the present invention.  As shown in this photomicrograph, the mean diameter of the microspheres is about
7.mu..  The microspheres are formed from one or more lipid monolayers or bilayers composed of saturated dipalmitoyl-phosphatidylcholine.  It will be understood, however, that other lipids may also be utilized.  It is preferred, nevertheless, that the
alkyl groups of the lipids thus selected be saturated and that the chains be from 16 or 18 carbon atoms in length.  Most preferred are alkyl chains having 16 carbon atoms.  The resulting gas filled microspheres are quite stable, and even relatively
diffusible and soluble gases, such as air, can be stabilized by such liposomal membranes.


FIG. 2 illustrates an apparatus for filtering and/or dispensing an MRI contrast medium comprising stabilized gas filled microspheres of the present invention.  This device consists of a cascade filter which may be fitted directly onto a syringe,
thereby allowing cascade filtration at the point of use.


FIG. 3 shows further detail regarding the filter.  The filter housing comprises a cascade filter assembly incorporated between a lower collar having male threads, and a female collar having female threads.  The lower collar can be readily secured
to the syringe and the upper collar is fitted with a needle.  An exploded view of the cascade filter assembly is also shown in FIG. 3.  It comprises two successive filters and in a preferred embodiment, the upstream filter is a "NUCLEPORE" 10 .mu.m
filter and the downstream filter is a "NUCLEPORE" 8 .mu.m filter.  Two 0.15 mm metallic mesh discs are preferably installed on either side of the downstream filter.  In a preferred embodiment, the filters and are spaced apart a minimum of 150 .mu.m by
means of a Teflon.TM.  O-ring.


FIG. 4 is a diagrammatic representation of the effect of the signal intensity of the microspheres on aqueous samples.  High speed fast GRASS imaging was performed on a 1.5 Tesla GE Signa, (Milwaukee, Wis).  Samples containing 5, 2.5 and 1.25 mg
per ml of lipid entrapping air, xenon and neon, i.e., all three concentrations for each sample, were prepared.  Briefly, the gas filled microspheres were prepared from an aqueous suspension of 5 mg per ml of dipalmitoylphosphatidylcholine in a buffer
prepared from 8 parts normal saline with 1 part glycerol and 1 part propylene glycol.  A 30 ml glass bottle with a rubber stopper was filled with each respective gas and vortexed for 10 minutes using a Vortex Genie-2 (Scientific Industries Inc., Bohemia,
N.Y.) at the highest power setting, 6.5.  The resultant stabilized microspheres were sized using an Accusizer optical particle sizer (Particle Sizing Systems, Santa Barbara, Calif.) and a Reichert-Jung Model 150 optical microscope (Cambridge Instruments,
Inc., Buffalo, N.Y.).  Half of the microspheres from each sample were extruded by hand using a syringe through an 8.mu.  filter (Nuclepore, Pleasanton, Calif.).  The microspheres prepared without extrusion had a mean size of about 20.mu..  The
microspheres which were extruded had a mean size of about 10.mu..  A portion of each of the samples of stabilized microspheres was then put into 25 cc syringes, partially filling the syringes.  A further portion of each sample was diluted 1:2 with normal
saline, and a still further portion of each sample was diluted 1:4 with normal saline.  The samples containing the nonextruded microspheres were larger than the extruded microspheres and the larger microspheres were noted to rise very rapidly towards the
top of the solution after vigorous shaking.


The invention is further demonstrated in the following working examples representing actual reductions to practice of the present invention.  The examples, however, are not intended to in any way limit the scope of the present invention.


EXAMPLES


Example 1


Magnetic Resonance Imaging Procedures Using Gas Filled Microspheres


One Sprague Dawley rat (approx. 500 gms) was anesthetized with 0.55 mL of 8:5:2, v:v:v, xylazine 20 mg mL.sup.-1, Ketamine 10 mg mL.sup.-1, and Acepromazine 100 mg mL.sup.-1.  Magnetic resonance imaging was performed on a Bruker Biospec 4.7 Tesla
magnet (Bruker Industries, Boston, Mass.) equipped with a Gradient Insert and Radiofrequency (RF) coil.  Precontrast imaging was performed with a GRASS Imaging gradient echo fast imaging (GEFl) with a time of repetition (TR) of 32 msec and a time of echo
(TE) of 8 msec.  The sedated rat was placed head first into the magnet probe and pre-contrast spin-echo images were obtained using the gradient insert and RF coil.  The following parameters were employed: Field of View=4 cm, Slice=3 mm, TE=5 msec, TR=32
msec, Number of acquisitions=1.  The data was stored as a 128.times.128 matrix.


The rat was catheterized with a 23 gauge butterfly catheter via the tail vein.  Upon determining the patency of the vein, 2.0 mL of gas filled microspheres were injected via slow IV push (duration approximately 10 sec).  The complete image
required approximately 8 seconds.  The image obtained with gas filled microspheres was significant for a profound darkening of the blood vessels in the brain, presumably outlining the circulations through the meningeal circulation.  It is further noted
that delayed imaging, i.e., after approximately 20 seconds, revealed restoration of the signal intensity through the blood vessels, indicative of the ability of this contrast agent to act as a first pass susceptibility agent.


Example 2


Gas Filled Microspheres As Susceptibility Agents In A Phantom Model For MRI


The procedures as described above in Example 1 were carried out.  To a 20 cc syringe was added 10 cc of a control mixture consisting of glycerol:normal saline (1:2, v:v).  To a second syringe was added 2.5 mL of gas filled microspheres mixed with
7.5 mL of a glycerol:normal saline (1:2, v:v) mixture.  Relative to the control, the gas filled microspheres sample was significant for producing a darkening of the MRI image at the top of the scan, indicative of a susceptibility agent that has floated
to the top.  Vigorous shaking of the gas filled microspheres sample was then found to be significant for producing a more uniform darkening of the test sample imaging relative to the control.  After five minutes, the sample was then re-scanned.  This
time the test sample was found to be significant for the same darkening of the image at the top relative to control, once again indicative of activity as a susceptibility agent.


Example 3


Gas Filled Microspheres


A 20 ml solution of 10 mg per ml lipid in an 8:1:1 vol normal saline:glycerol:propylene glycol was prepared using an 82 mole percent dipalmitoylphosphatidylcholine (DPPC): 10 mole percent dipalmitoylpshosphatidic acid (DPPA): 8 mole percent
dipalmitoylphosphatidylethanolamine-PEG 8,000 mixtures of lipids (all lipids from Avanti Polar Lipids, Alabaster, Ala).  The lipids were shaken on a vortexer [VWR Genie-2 (120V, 0.5 amp, 60 Hz.) Scientific Industries, Inc., Bohemia, N.Y.] for 10 minutes
creating a foam height of about 100 cc.  The above was then mixed with a 0.5% by weight suspension of xanthan gum in 800 cc of water to yield a final volume of about 900 cc.  The resulting contrast medium composed of gas filled microspheres formulated
from the foregoing lipids was judged to have good contrast and to be suitable for ingestion for contrast of the gastrointestinal (GI) tract.


Example 4


Gas Filled Microspheres


The procedures in Example 3 above were repeated except that distearoylphosphatidylcholine (DSPC) was used instead of DPPC.  The resulting microspheres was judged to be superior to the DPPC microspheres and again highly suitable for ingestion as a
GI MRI contrast agent.


Example 5


Gas Filled Microspheres


The procedures used above in Examples 3 and 4 were repeated, except that nitrogen gas was used instead of air.  The resulting microspheres were judged to be somewhat more stable that those which utilized air, i.e., a larger amount of the foam
height was retained upon incubation at 40.degree.  C. for the DPPC microspheres and at 50.degree.  C. for the DSPC microspheres, when nitrogen gas was used to prepare the microspheres, than when air was used.


Example 6


Gas Filled Microspheres As Susceptibility Agents In a Phantom Model For MRI


Samples of the microsphere based GI contrast media prepared in Examples 3-5 were assessed as MRI contrast agents by scanning phantoms in clinical MRI imaging devices.  Three different devices were tested, 0.5 and 1.5 Tesla GE Signa magnets (GE
Medical Systems, Milwaukee, Wis.) and a 4.7 Tesla Bruker, Biospec II (Bruker, Billerica, Mass.).  T1 weighted pulse sequences were tested including T1 weighted spin echo sequences, TR=250 msec/TE=12 msec, T2 weighted fast spin echo pulse sequences (0.5
and 1.5 Tesla only) TR=4000 msec with TE=19 (echo train=4) and 105 msec (echo train=16) and T2 weighted spin echo pulse sequences TR=2,500 msec and TE=25, 50, 75, 100, 125 and 150 msec using a bandwidth of 8 kilohertz.  The T2 weighted spin echo pulse
sequences were repeated using a bandwidth of 32 kilohertz.  Gradient echo pulse sequences were also tested using a TR of 50 msec and TE of 5, 10, 15, 20, 25, 30 and 35 msec using a flip angle of 30 degrees and a bandwidth of 8 kilohertz; the foregoing
was repeated with a bandwidth of 32 kilohertz.


The resultant images showed field-strength dependent contrast with decreased signal in the phantom due to the stabilized microspheres most evident on the 4.7 Tesla magnet and in turn more evident on the images at 1.5 Tesla than at 0.5 Tesla.  The
contrast effect was progressively more pronounced on more highly T2 weighted images, i.e., the longer the echo time the greater the degree of signal loss.  Little effect was shown on the T1 weighted images at 0.5 Tesla but progressively more signal loss
was evident even on the T1 weighted images at 1.5, and even more at 4.7 Tesla.  On the spin echo images changing the bandwidth had no appreciable effect; but on the gradient echo images the degree of signal loss was much more pronounced on the extended
read-out, i.e., narrow bandwidth 8 kilohertz images, than on the 32 kilohertz images.  Greater contrast was shown on the gradient echo images in general than on the spin echo images.  The contrast effect caused by the gas filled microspheres was about
the same for the air and nitrogen gas filled microsphere preparations.


Example 7


Gas Filled Microspheres Containing A Paramagnetic Contrast Agent


Microspheres were prepared as in Example 4 except that a solution of 0.75 millimolar manganese chloride was added to the suspension of xanthan gum and this was then mixed with the microspheres.  MR imaging was repeated as in Example 6, and it was
found that the degree of signal darkening, i.e., contrast effect, was even more marked than before.  The contrast was, furthermore, found to be biphasic with increased signal intensity shown on the very shortest echo time T1 weighted images.  By
comparison, a phantom containing a solution of 0.75 millimolar manganese chloride was scanned; the degree of contrast caused by the manganese chloride solution alone was much less than that for the combined microsphere and paramagnetic particle
suspension.


Example 8


Gas Filled Microspheres Prepared Using A Gaseous Precursor


In the foregoing examples of gastrointestinal MRI stabilized gas filled microsphere based contrast agents, the microspheres would be preformed prior to ingestion of the contrast agent.  While this is highly effective, gaseous precursor based
suspensions can be formulated so as to be more palatable and easily tolerated by the patient.


A precursor GI contrast agent formulation was prepared by mixing a 20 mg per ml concentration of lipids as described in Example 4 with 20 mg per ml of peanut oil and 600-1200 .mu.L of bromochlorofluoromethane, an amount sufficient amount to
generate approximately 0.15 L-0.30 L of gas.  The above was mixed by vortexing for 10 minutes, although sonication could also have been used, and in turn 100 cc of the gaseous precursor emulsion was then mixed vigorously with 750 cc of a 0.85% suspension
of xanthan gum which contained 3% by weight propyleneglycol and 3% by weight glycerol.  The above was then scanned by magnetic resonance imaging at room temperature.  On MRI the precursor suspension had little contrast compared to a control suspension of
0.85% xanthan gum in water.


A sample of the precursor contrast medium was then placed in a water bath at 40.degree.  C. and shaken intermittently Bubbles were noted to form in the emulsion.  Because of the xanthan gum viscous suspension, the bubbles appeared to remain
within the suspension rather than immediately floating to the top.  On MRI the contrast medium was found to have similar contrast as that in Example 6.


Example 9


Gas Filled Microspheres Prepared Using A Gaseous Precursor


The same procedure as in Example 8 was used, except that 1,1 dichloro-1-fluoroethane was used in a sufficient quantity to generate 150 mLs of gas upon undergoing a phase transition at 38.degree.  C. (MW 116.95, bp 38.degree.  C., density=125
g/mL).


Example 10


Gas Filled Microspheres


A 5 ml solution of 5 mg per ml lipid comprising 8:1:1 volume ratio of normal saline:glycerol:propylene glycol was prepared using a mixture of 77.5 mole percent DPPC+12.5 mole percent DPPA+10 mole percent of
dipalmitoyl-phosphatidylethanolamine-polyethyleneglycol (DPPE-PEG 5000) a lipid covalently bound to a hydrophilic polymer.  Air was evacuated from the 18 ml glass vial entrapping the lipids and the vial was filled with nitrogen to ambient pressure.  The
material was autoclaved at 121.degree.  C. and elevated pressure for 15 minutes and allowed to cool to room temperature.  The vial was shaken on a Wig-L-Bug brand shaker for 2 minutes, yielding a thick foam of about 12 cc volume of gas filled
microspheres.  The size of the gas filled microspheres was determined by Accusizer and found to be as follows: mean size about 5.mu.  with 99.9% of the particles below 15 microns in size.


Example 11


Gas Filled Microspheres Prepared Using A Gasseous Precursor


Example 10 was substantially repeated except that instead of nitrogen the head space in the vial about the lipids was filled with perfluorobutane (decafluorobutane) to ambient pressure, autoclaved and shaken as described above, yielding a volume
of gas filled microspheres of about 16 cc.  The resultant size of the gas filled microspheres was found to be mean size about 5.mu.  and 99.9% cut-off at about 25.mu..  A portion of these perfluorobutane microspheres was then placed in a 3 cc syringe and
subjected to a single injection through a filter with 8.mu.  filter pore size.  The mean size of the resultant microspheres was about 3 to 4.mu.  with 99.9% at about 11.mu.  or below.


Example 12


Gas Filled Microspheres Prepared Using A Gaseous Precursor


The procedures above in Example 11 were repeated with octaperfluoro-cyclobutane, with substantially the same results being obtained as in Example 11.


Example 13


Gas Filled Microspheres Prepared Using A Gaseous Precursor


The procedures above in Example 11 were repeated, except that instead of the diluent 8:1:1 normal saline:glycerol:propyleneglycole normal saline with 5% by weight polyvinylalcohol (PVA, weight average molecular weight about 5,000) was used as the
diluent.  The same procedure was then followed for formation of the perfluorobutane filled microspheres.  The mean size of the gas filled microspheres was about 3 to 4.mu., but the 99.9% cut-off was even smaller at about 11.mu.  without the filtration
step.


Example 14


Gas Filled Microspheres Prepared Using A Gaseous Precursor


The procedures above in Example 11 were repeated except that 50 microliters of dodecaperfluoropentane (perfluoropentane, boiling point about 27.degree.  C.) was injected into the vial containing the liquid lipid suspension.  In this case the air
head space was not removed and the injection of the perfluoropentane was performed at -20.degree.  C. The vial was then autoclaved at 121.degree.  C. and elevated pressure for 15 minutes.  The vial was then placed in a 30.degree.  C. incubator and the
temperature allowed to equilibrate.  The sample was shaken for 2 minutes on the Wig-L-Bug brand shaker and the entire vial was then filled with foam.  A portion of this foam was withdrawn and it was noted that the contents within the vial were under
increased pressure.  A portion of this foam was sized yielding a mean size of 5.8.mu., a 95% cut-off of 19.1.mu.  and a 99.9% cut-off of about 75.mu..  When a portion of this foam was extruded through the syringe with the 8.mu.  filter, the mean size was
about 3 to 4.mu.  with a 99.9% cut-off at about 10.mu..


When the above procedures were repeated, except that the vial head space comprising air was evacuated prior to shaking the gaseous perfluoropentane, the mean size of the resultant microspheres was larger than when the microspheres were prepared
under pressure with the head space comprising air.


Example 15


Effect of Different Gases on Size Distribution and MRI R2 Relaxivity of Gas Filled Microspheres


Samples of gas filled microspheres prepared by agitating aqueous lipid solutions comprising 5 mg per mL of DPPC, DPPA and DPPE-PEG5000 in a mole ratio of 82%:10%:8%, respectively, in separate atmospheres of oxygen (O.sub.2), air, nitrogen
(N.sub.2), xenon (rubidium enriched hyperpolarized), neon, argon, sulfur hexafluoride (SHF or SF.sub.6), perfluoropropane (PFP) and perfluorobutane (PFB) gas.  The samples were agitated using a Wig-L-Bug.TM.  at 3300 RPM for 60 seconds.  The resultant
gas-filled liposome samples were then suspended in 4% methyl cellulose in normal saline, to prevent the liposomes from floating to the top during imaging experiments.


Portions of each sample were then placed in plastic syringes and held within a radial array phantom holder which included tubing, a pressure gauge and a syringmamometer, for magnetic resonance imaging.  Samples containing 20%, 10%, 5%, 2.5%,
1.25% and 0.625% by volume of each gas were then scanned by magnetic resonance using a Brinker Biospec II 4.7 Tesla scanner (Bruker, Billerica, Mass.).  T2 measurements were performed by scanning the samples with Spin Echo Sequences TR=800 msec and
TE=30, 45, 60, 75 and 90 msec and gradient echo sequences for signal intensity measurements with TR=60 msec, TE=8 with a 40% flip.  Signal intensities were measured by selecting region of interest on the CRT monitor.  For T2 measurements the signal
intensity data was plotted and the R2 (1/T2/mmol/L.sec-1) was determined for each gas by using the standard gas law to determine the millimolar concentrations of the gas and fitting the T/T2 data versus concentration.


The effect on the various gases on R.sub.2 and liposome sizes are shown in the table below.  The relationships between 1/T.sub.2 versus gas concentrations for the different gases are shown in FIGS. 5A and 5B.


 TABLE 3  ______________________________________ Size Distribution and Relaxivity  Number Weighted  Volume Weighted  Gas Distribution Distribution R2  ______________________________________ N.sub.2  6.96 +/- 0.63  31.08 +/- 7.42  474.6 +/- 59.9 
SF.sub.6  4.31 +/- 0.13  44.25 +/- 1.23  319.3 +/- 42.5  Xenon 7.02 +/- 1.19  160.90 +/- 92.46  191.2 +/- 30.8  Argon 8.14 +/- 0.49  41.45 +/- 13.02  55.29 +/- 41.3  Air 6.05 +/- 1.05  23.28 +/- 0.41  1510.4 +/- 0.41  PFP 4.24 +/- 0.72  49.88 +/- 11.11 
785 +/- 31.8  O.sub.2  7.26 +/- 0.98  30.99 +/- 3.90  732.4 +/- 73.9  Neon 7.92 +/- 0.71  26.20 +/- 1.03  595.1 +/- 97.2  PFB 5.88 +/- 0.36  51.25 +/- 3.97  580.1 +/- 45.5  ______________________________________


Example 16


Effect of Pressure on MRI 1/T2 and Signal Intensity of Gas-Filled Liposomes


The gas filled microspheres of Example 15 were scanned during exposure to pressures of 0, 50, 100, 150, 200, 250, and 300 mm of Hg.  The results are shown in FIGS. 6-9.  Specifically, FIG. 6 shows a diagram of the effect of pressure on gas-filled
liposome size.  FIG. 7 shows the effect on 1/T2 of 2.5% by volume neon and FIG. 8 shows the effect on 1/T2 of 2.5% by volume PFP upon exposure to pressure.  FIG. 9 shows the effect on signal intensity in nitrogen gas-filled liposomes using a gradient
echo pulse sequence upon exposure to pressure.


Example 17


Effect of Pressure on MRI 1/T2 and Signed Intensity of Gas-Filled Liposomes


Ten cc of a suspension of gas-filled liposomes comprising of 20 mole % PFP, 70 mole % air and 10 mole % .sup.17 O.sub.2 gas is injected into a patient with an aortic coarct.  Gradient echo pulse sequences are performed by MRI and the signal
intensities are measured as well as 1/T.sub.2 * across the coarct.  By looking at the increase in signal intensity or decrease in 1/T.sub.2 * across the coarct a pressure gradient is estimated by magnetic resonance imaging.


The disclosures of each patent, patent application and publication cited or described in this document are hereby incorporated herein by reference, in their entirety.


Various modification of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description.  Such modifications are also intended to fall within the scope of the appended claims.


* * * * *























								
To top